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Abstract
Controlled thrombosis initiates and regulates tissue repair and remodeling in the
vessel wall. Processes from heart attack to stroke, and deep vein thrombosis to pulmonary
embolism, are all derived from unrestricted clotting. The frustrating aspects of these
diseases lie not only in the difficulty of their timely diagnosis, but in the selection of
appropriate therapy, titration of intervention, and identification of patients at risk. Assays
like the INR, PTT, and ACT can follow the course of specific pathways that govern
activation of specific coagulation factors or platelet function, but they do not provide the
insight into mechanism, risk and potential therapeutic benefit.
We posit that elucidation of the complex dynamics of clot generation requires an
integrated assessment that takes into account all of the factors driving thrombosis
simultaneously. Virchow's Triad, has for years been identified as the three critical
parameters of clot formation. We propose to examine an individual's clot propensity and
response to therapy on minute blood samples, in virtual real time, across a range of flow
rates, blood state, and wall conditions with the use of our newly developed in vitro high-
throughput testing device. In this manner we will generate a unique thrombotic
fingerprint that defines an individual's risk of clotting at a specific point in time over a
range of stresses. This fingerprint can aid in tailoring therapeutic clinical treatments,
determining the duration and dose of therapy, and assist in clinical trial management and
establishment of clinical norms.
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CHAPTER 1: INTRODUCTION
The past decade has brought along rapid evolution of the pathophysiological
understanding of coronary artery disease (CAD). Initially considered a cholesterol
storage disease, the current body of knowledge indicates that a more complex
interaction between risk factors such as endothelial cells of the artery wall, the
blood and its components, and the messages exchanged between the two, are at the
center of atherogenesis.
1.1 CORONARY ARTERY DISEASE
The formation of a CAD lesion begins with an interaction between the
arterial endothelium and bacterial products, or any number of a variety of risk
factors, including dyslipidemia, vasoconstrictor hormones due to hypertension,
glycoxidation products present during hyperglycemia, or proinflammatory
cytokines derived from excess adipose tissue [1]. During this interaction, the
endothelial cells increase the production of adhesion molecules, known as
chemoattractant cytokines, which attract blood leukocytes to the interior artery
wall surface. At this point, leukocytes, which are mainly composed of mononuclear
phagocytes and T lymphocytes, begin communication with the endothelial and
smooth muscle cells of the intima. An inflammatory response is initiated, and during
the early atheroma, smooth muscle cells migrate from the tunica media into the
intima, proliferate, and compose a complex extracellular matrix. To maintain the
inflammatory response, a number of metalloproteinases (MMPs) are released to
modulate a variety of functions of the vascular cells, including activation,
proliferation, migration, new vessel formation, remodeling, healing, and cell death.
Calcification may occur by mechanisms similar to those which form bone [2]. In
addition, cell death, especially the death of lipid-laden macrophages, soon becomes a
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common occurrence. This accumulation of extra-cellular lipid eventually grows to
form the lipid-rich necrotic core of the atherosclerotic plaque [1].
During the process of plaque formation and growth, the geometry of the
plaque contributes to remodeling of the vasculature. For a number of decades, the
narrowing of the artery (stenosis) due to the formation of a plaque was considered
the main threat of this condition. More recently, it was found that an atherosclerotic
lesion actually grows outwardly for the majority of its life, instead of into the lumen
[3, 4]. (Lesions of the stenotic and non-stenotic variety are shown in Figure 1.)
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Figure 1: Stenotic and non-stenotic lesions [1].
These findings indicated an understanding of the process of lesion formation
unable to encompass the large number of atherosclerotic lesions that could exist
without producing stenosis [3, 4]. In addition, it was found that by the time lesions
had developed to the point of causing stenoses, intimal atherosclerosis could be
found widespread through the vasculature of the patient [5].
The growth of stenoses has been found to transpire through a series of
sudden spurts, rather than smoothly and continuously [6, 7]. This effect may be due
to acute disruptive episodes of the atherosclerotic lesion, followed by thrombosis at
the site, and a healing process that may actually further exasperate the obstruction
of blood flow. The process by which a plaque is disrupted and healed by the body is
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an area of great interest, and requires a closer look at the interaction between the
lesion and the components of the blood around it.
1.2 THE PLATELET AND THE COAGULATION CASCADE
The platelet is a small anucleate cell produced in the bone marrow by
megakaryocyte cells, and in the absence of vessel wall injury, can circulate in the
blood for 8-11 days. A normal platelet count varies from 150,000 to 300,000
platelets/mm 3 blood. Platelets in their quiescent state are generally unreactive to
their environment but can easily be activated by interaction with endothelial
subcomponents and external membrane glycoproteins. During this activated state,
the platelets can perform several functions [8]:
1) Adhere to injuries in blood vessels to form the primary hemostatic plug that
prevents the loss of blood.
2) Provide a surface on which soluble coagulation factors can react.
3) Promote the integrity of the endothelium by sharing metabolic products with
it.
4) Release a variety of chemical regulators that can control vascular tone,
regulate inflammatory reactions, and initiate the repair of damage in vessels.
The clotting mechanism in mammals begins with damage to the vascular system,
which simultaneously initiates two pathways - one is the aggregation of blood
platelets at the site of injury, the other is the activation of the enzymes of the
coagulation cascade.
Platelet activation begins with the blood exposure of subendothelial components
of the vascular wall due to vessel injury. The platelet adheres to exposed collagen
and other components, conformationally changes, and undergoes a primary release
of regulators by means of dense and alpha granules. There are normally about ten
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dense granules in each platelet, which contain ADP, ATP, calcium, serotonin, and
vasopressin. There are about ten times as many alpha granules, which contain a
large variety of coagulation proteins including fibrinogen, fibronectin, factor V, and
vWF [8]. The release of the products contained in the granules initiates the
coagulation cascade (Figure 2).
Extrinsic Intrinsic
pathway pathway XII
VII--V11a V
I IX I Xl-
VIWaTF Xla
Ca 2+C
PL IXa
' VIlla 1 VIII
x go Xa A
C&
2
+ Va -* V
PL
Fibrinogen bbren
monomner
Fibrin
polymer
1 -- X111a -4- XIII
Crosslinked
fibrin
polymer
Figure 2: Schematic representation of the coagulation cascade [9].
VWF interacts with subendothelial structures in a calcium dependent process,
leading to an alteration of the structure, such that it will recognize specific receptors
on the platelets' surface. The release of ADP from the adherent platelets stimulates
even more platelets to aggregate together to generate thrombin on the platelet
surface, and form the primary hemostatic plug. Finally, conversion of fibrinogen to
fibrin strands by the high concentrations of thrombin in the plasma, links one
platelet to another to solidify the platelet plug, forming the secondary hemostatic
plug [10].
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During the coagulation cascade, several aspects of the vascular environment
serve to control the reaction and limit the extent of blood coagulation. First, the
continued flow of blood past the growing platelet plug washes away loosely adhered
platelets and helps to dilute the concentrations of soluble regulators in the plasma.
The plasma also provides ADPases which help degrade ADP to adenosine, a
competitive inhibitor of platelet aggregation. Finally, the endothelial cells around
the injury produce prostacyclin (PGI 2), which serves as an additional platelet
inhibitor [8].
1.3 ARTERIAL THROMBOSIS
Thrombosis is the formation of a blood clot in the vasculature by means of the
coagulation cascade and platelet interactions. As explained earlier, atherosclerotic
plaques contain a fibrous cap that keeps separate the highly reactive components of
the plaque and subendothelium from the platelets and soluble regulators found in
blood. Thus, it would be expected that a physical disruption of the plaque accounts
for the majority of acute coronary thromboses. These disruptions are resultant from
a variety of events (Figure 3).
Emilge at CdW. c"ui SeuaPaqu. Nmh
Figure 3: Disruptions of the atherosclerotic fibrous cap [1]. The cases are explained
in the text.
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The case in which the fibrous cap is ruptured accounts for about 66-75% of
fatal coronary thromboses [1]. In this scenario, rupture may occur due to two
factors. First, chemical factors released from inflammatory cells within the lipid-
laden core of the plaque can compromise the integrity of the fibrous cap. For
example, cells within lesions produce enzymes that act upon the interstitial matrix,
degrading the cap's strength. Secondly, physical stresses applied to the plaque may
aid in its rupture. A fibrous cap weakened by chemical means is especially subject to
stresses caused by blood pressure and blood flow in the "shoulder" region of the
plaque, where the plaque borders the normal arterial wall. These types of events are
most likely to occur during moments of strenuous physical activity or emotional
upset [11]. In certain populations, such as diabetic individuals and women,
superficial erosion of the plaque by way of exterior hydrodynamic stresses are
actually more common causes of fibrous cap disruption. Also, microvessels in the
base of the plaque may rupture, causing intraplaque hemorrhage. The combination
of hemorrhage and local generation of coagulation regulators in the plaque can
cause sudden lesion expansion into the vessel lumen (Figure 4).
Figure 4: Partial lumen area reduction by thrombosis caused by plaque disruption
(left). Complete blocking of the lumen by thrombosis caused by plaque disruption
(right) [12].
The condition of the blood surrounding the plaque can also play a large role
in its disruption. Subjects with diabetes, obesity, or hypertension experience
heightened levels of circulating plasminogen activator inhibitor-1 (PAI-1), which
helps to decrease the body's natural fibrinolytic mechanism - the mechanism that
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combats the persistence and accumulation of thrombi. This type of blood condition
has led to patients being diagnosed as "vulnerable patients" due to their
predisposition toward coronary thrombosis [1, 13].
Following the disruption of the plaque, the blood coagulation pathway is
begun by exposure to tissue factor originating from the lesion's atheromatous core,
while exposure to subendothelial collagen fibrils activates platelets. In addition,
regulators cause narrowing of the blood vessel, which in turn creates turbulence,
increases blood shear rate at the vessel wall, and activates more platelets. As an
additional positive feedback measure, the resulting reduction in coronary blood
flow decreases the washout of coagulation proteins, further enhancing
thrombogenicity [13].
1.4 THERAPY FOR ACUTE CORONARY SYNDROMES (ACS)
The concept of the "vulnerable patient" has brought about a new look at acute
coronary syndromes, where the search for plaques at high risk of causing
thrombotic complications has become a high priority. As the majority of lesions
grow outwardly and do not encroach on the artery's lumen, searching for vulnerable
plaques by traditional angiographic means has proven to be difficult. It has become
necessary to monitor the plaque morphology, and not simply the degree of luminal
obstruction. Other means of studying these plaques, such as ultrasound, have shown
multiple disrupted lesions in patients, challenging the traditional view that ACS is a
localized disease that deserves localized therapies such as bypass surgery [1].
Analysis of these plaques has resulted in a set of characteristics of a vulnerable
plaque:
* Lipid core comprises 50% of plaque volume
" High density of macrophages
* Low density of SMCs in the cap
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0 High tissue factor content
* Thin plaque cap in which the collagen structure is disorganized
The chance a patient with CAD may encounter an ACS depends upon the number
of vulnerable plaques present in their vasculature, rather than simply on the
number of plaques. This relationship can be noted in variations in frequency of
infarcts in particular patients. Some patients may experience them relatively
frequently, while others may go ten to twenty years after an infarct with no
reoccurrences [12].
Currently, therapy for ACS includes two phases. Early on, the acute phase of the
treatment is instituted whereby death of cardiomyocytes is reduced by addressing
the features of a thrombotic event that reduce flow to areas of the heart through
embolization. The second phase of therapy involves management of the patient's
condition by means of a combination of drugs to inhibit platelet activity and
thrombin generation. In addition, percutaneous or surgical revascularization to
stabilize the culprit lesions may help greatly in high-risk patients. The drug cocktail
during this portion of the therapy includes oral aspirin, clopidogrel, and an
intravenous glycoprotein Ilb/Illa during the angioplasty [1].
This revision on the classic views of atherosclerosis has left a great impact on
patient care. The need to systemically prevent episodes of ACS in individuals at risk
has been highlighted. A more individualized therapy based on specific patient
characteristics, may be an efficient and cost-effective solution for preventative
therapy in the future.
1.5 VIRCHOW'S TRIAD
Rudolf Virchow (1821-1902) is recognized as the discoverer and originator
of a number of advances in medicine that continue to influence physicians today.
One theory that has been somewhat incorrectly attributed to him (the ideas were
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neither original to Virchow, nor did he synthesize them in the manner currently
understood by physicians [14]) for over 150 years has been a theory which explains
the pathogenesis of venous thrombosis, Virchow's Triad. The theory suggests that
three criteria must be met to begin thrombogenesis: abnormalities of the vessel
wall, altered blood states, and altered blood flow conditions [15].
1.5.1 VESSEL WALL CONDITIONS
Under normal healthy conditions, the endothelium of the vessel wall
prevents blood coagulation and platelet activity by means of glycoproteins on the
endothelial cell surfaces as well as the release of a variety of molecules.
Glycoproteins such as ectonucleotidase, reduce the coagulant activity of blood by
minimizing the pro-thrombotic effects of nucleotides like ADP [16].
In the acute time frame of endothelial damage, a highly reactive set of
subendothelial components are exposed to a great deal of blood full of components
ready to initiate the coagulation cascade. In the chronic time frame of abnormal
vessel wall conditions, where the endothelium may be damaged or dysfunctional, a
number of molecules normally held within the cell are present in elevated amounts
in the plasma [15, 16]. This change in the particulate composition of plasma can be
interpreted as the endothelium's response to injurious stimuli, which brings about a
change in the function of the endothelial cells. Specifically, measurements of the
plasma concentration of certain molecules are often used as markers of endothelial
disruption and dysfunction. Variations in these plasma concentrations have been
found to accurately predict cardiovascular events, mortality, and morbidity [17].
Increased levels of von Willebrand's Factor (vWF) is a common marker of
atherosclerosis, and unless the atherosclerotic condition is dealt with, the high
levels of plasma vWF may actually increase the risk of thrombus formation in
patients with atherosclerotic lesions, further reinforcing the diseased condition
[17]. Another marker used to indicate vascular disease states is thrombomodulin, an
important regulator of thrombin. When functioning correctly, thrombomodulin is a
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cell membrane protein that converts thrombin from a procoagulant to an
anticoagulant. Release of the protein from the cell into the plasma tips the
hemostatic balance of the blood to a more pro-coagulant state [16]. The
endothelium is considered the largest complex functional organ, and from these
serological methods (measurement of plasma composition), it can easily be seen
that it has a great influence on disease states of the cardiovascular system.
1.5.2 BLOOD STATE
The next component of Virchow's Triad refers to the condition of the blood
and any abnormalities in its constituents, such as the increased presence of clotting
or hemostatic factors or activated platelets [15]. The process of thrombogenesis is a
balance between the fibrinolytic system and the platelets. The fibrinolytic system is
first influenced by plasminogen activators and inhibitors. A plasminogen activator
such as tissue plasminogen activator (tPA) helps to promote fibrinolysis, while an
inhibitor such as plasminogen activator inhibitor-1 (PAI-1), helps to modulate the
fibrinolytic process. Maintaining a correct balance between these two factors is
highly important in avoiding a pro-thrombotic blood state. For example, normally a
male patient has a 1:8 ratio of active tPA to active PAI, but atherosclerotic men
experiencing a more pro-thrombotic blood state may show a severe disturbance in
this ratio, approaching 1:50 [15].
Other soluble coagulation factors have been found in increased levels during
disease states. High concentrations of fibrinogen, an essential component of the
coagulation cascade, have been found in conjunction with many forms of
cardiovascular and inflammatory diseases, as well as smoking, physical inactivity,
and obesity. In addition, increased fibrinogen has a number of prognostic
implications for cardiovascular death and nonfatal myocardial infarction, raising the
risk cardiovascular events in a patient [17].
The other half of the blood state balance involves the activation of platelets.
Platelet activation occurs as a result of cell interaction with any one of a number of
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soluble factors or subendothelial wall components. Activation of the platelet causes
its integrin receptors to change from the low to high affinity state, supporting the
firm adhesion of the platelets onto fibrinogen, collagen, and fibronectin surfaces
[18]. The steps following activation and adhesion of the platelet include spreading of
the cell onto the surface and aggregation of other platelets to the site, forming the
primary hemostatic plug.
1.5.3 THE LOCAL HEMODYNAMIC SETTING
Altered hemodynamic states forms the last leg of Virchow's Triad. Of interest
in this realm is the rheology of blood, especially the viscosity of the blood and the
shear force with which it impinges on the vessel walls. As a non-Newtonian fluid, the
viscosity of blood is not a constant, but variable according to the shear rate
experienced by the blood. In conditions of low shear rates, or stasis, hyperviscosity
of blood may occur, initiating coagulation, causing atherogenesis, endothelial cell
dysfunction, thrombogenesis, and ischemia [15]. On the other hand, elevated shear
rates have a hand in platelet activation, initiating the coagulation cascade from
another pathway.
The local flow state inside a vessel greatly influences the biological
interactions, be them on the molecular, microscopic, or macroscopic scales. On the
molecular level, the transportation of substances from a source, like the blood, to an
activating locus, like a receptor, by means of diffusion or convection, plays an
important role [18]. Microscopic interactions also play a role in the hemostatic
environment. As blood flows through the vasculature, the Fahrous-Lindqvist effect
causes the hematocrit, composed of red blood cells, to migrate towards the
center of the vessel lumen, displacing the platelets to the flow periphery. Due to
this, fluid shear at the wall combined with cellular transport mechanisms and
endothelial wall activity become an important factor in the process of
thrombosis [19, 20]. Finally, in the macroscopic realm, high shear forces or
pressure fluctuations can have a significant impact on the spread and
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progression of disease states such as acute thrombotic events. These types of
events involve the sudden rupture of atherosclerotic plaques due to the fact that
the plaque fibrous cap strength is too weak in relation to the local fluidic forces
[21-24].
As the local flow field yields a great amount of influence over the
biological response of the area, physiological attributes of the vasculature that
affect the flow also play a large role by association. Simple profiles are to be
found in purely axial flows where dimensional symmetry abounds in the vessel.
On the other hand, curved flow streams cause additional axial and orthogonal
pressure gradients, which in turn bring about secondary and recirculant flows
[25, 26]. These complex flows, in turn, bring about changes in the shear stresses
applied to the vessel walls by the fluid. These effects are normally essential in
the remodeling and maintenance of healthy vessels, but at times can prove
detrimental to the vessel health, and actually help progress vascular disease.
This effect can be noted in the substantially higher rate of atherosclerosis at
sites of vessel curvature and branching, as compared to areas of little to no
curvature [27, 28].
The three main vascular environmental parameters that affect the
thrombotic process have been briefly described. The goal of the following study is to
encompass these three thrombotic controls in a testing mechanism and allow them
to be manipulated and studied in a controlled fashion. The result will be a highly
individualized body of data consisting of a given patient's potential for thrombosis
across a vast range of physiological and iatrogenic conditions, from here on known
as a "thrombotic fingerprint". We posit that the generation, study, and refinement of
the thrombotic fingerprint will help to gain further insight into the nature of
thrombosis and the clinical response to the disease state, as well as aid in tailoring
therapeutic clinical treatments, determine the duration and dose of therapy, and
assist in clinical trial management and establishment of clinical norms.
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CHAPTER 2: METHODS OF STUDYING THROMBOSIS
2.1 TRADITIONAL MODELS
A number of methods to study the process of thrombosis under controlled
conditions are currently available to researchers and clinicians. This group of
models can be split between the in vitro, in vivo, and ex vivo varieties. Each one of the
tests offers a unique and useful insight into thrombogenesis, while providing a
particular set of constraints due to the nature of the testing. These constraints may
be realized in the parametric conditions tested, or in the types and extent of
information derived from test results. Over time, the combination of these tests has
greatly helped to further the body of knowledge regarding vascular biology. Briefly,
the current set of tests used to study thrombosis, as well as the particular insights
and advances they have provided, will be described.
2.1.1 IN VIVO MODELS
The main advantage of in vivo models is their high degree of realism and
physiological relevance that is in most cases, unattainable in the realm of in vitro
testing. In vivo models include clinical trials and animal studies. These two types of
tests allow for monitoring of the complex biological interactions occurring inside a
subject for long periods of time. These enhanced observational aspects improve
disease characterization, patient risk stratification, and the efficacy of therapeutic
options [18]. In general, mechanistic and pathological insights have been acquired
by observing the human condition, especially during moments of overt system
failure. By these means, several important processes related to thrombosis have
been initially discovered, such as GPVI deficiency, Glanzmann's thrombasthenia,
Bernard-Soulier, GPIb deficiency, and vWF disease [29]. Among the variety of tests,
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clinical trials are the most relevant to the human condition, and due to the fact that
the primary goal of the trial is to help the patient, making progress on the scientific
front generally proves difficult. The long time scales of these projects, as well as the
lack of ideal condition controls and the inherent patient variability, can frequently
lead to increasingly complicated results which may yield unclear conclusions.
The next step away from the human model is the animal study. In these cases
a detailed observation of the physiologic environment can be obtained with the
added benefit a tighter control over the experimental conditions. A wide variety of
animals are used in the study of thrombosis and vascular biology. The decision on
what animal to use in a model is based on the balance of testing condition
requirements. Large animals may better represent the architecture of the human
vasculature to apply results more directly to the human model, while small animals
are more easily manipulable and cost less, allowing for fundamental questions to be
probed. The animal study is still limited, although less so than the human clinical
study, by the list of parameters that may reasonably be manipulated [30-33].
2.1.2 IN VITRO MODELS
In vitro models give researchers the added benefit of a much tighter
parametric control over the variables governing thrombosis. Powerful
manipulations may be performed on isolated biological components, while under a
highly consistent set of hemodynamic and physical conditions. In general, these
systems may be categorized into models that either maintain physical geometric
properties, or those that maintain the physiological flow properties [18].
2.1.2.1 MODELS THAT MAINTAIN PHYSIOLOGICAL GEOMETRY
The group of in vitro models that focus on maintaining physical geometric
properties, such as realistic vascular dimensions, have been utilized in a variety of
studies, ranging from endovascular device thrombogenicity to cellular adhesion in
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vascular deformities. Of great importance in all of these models is the method by
which the blood flow is actuated and maintained. A variety of solutions have been
formulated by researchers, such as gravitationally powered one-pass flows and flow
loops. Systems powered by gravity feature the benefits of a high predictability and
control, low noise, and simple set up, but encounter issues with large static volumes
of blood which limit the experimental flow rates and run times [33]. Some flow loop
systems feature a tubing loop partially filled with blood, mounted on a tilted
turntable, and spun about the center of the loop to induce motion of the blood
relative to the walls of the loop. These systems improve upon the gravitationally
actuated flow systems by utilizing small blood volumes, but suffer from problems
stemming from the recirculation of blood and the inbuilt air-fluid interface [34-36].
The next iteration in flow system design was the use of pumps (such as
peristaltic pumps) to actuate and control the flow through a circuit. Unfortunately
these systems generate excessive background noise from unwanted mechanical or
electro-magnetic activation of blood components, resulting in a system whose
environment is too traumatic to correctly replicate arterial-like flow conditions [37,
38].
2.1.2.2 MODELS THAT MAINTAIN PHYSIOLOGICAL FLOW
CHARACTERISTICS
The second category of in vitro thrombosis models seek to reproduce the
vascular flow conditions. The models that replicate the geometry of the vasculature
are typically constrained by the range of shear rates they can elicit. Models that
forgo the need to model the exact geometry of the vasculature, but instead focus on
the flow conditions, make use of small circuit geometries that allow the
development of high shear rates with low volumetric flow rates, such as parallel-
plate flow chambers [39-43]. In addition to maintaining physiological flow
conditions, these systems have been extremely useful due to their tight biological
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environment control and their ability to offer microscopic visualization of surface-
cellular interactions in real time.
Other techniques that maintain physiological flow conditions include cone-
plate and annular ring devices. These systems create a relative motion between a
fluid and two of the surfaces which contact it, creating a Cuvette-type flow. Although
these models take great liberties with the physical flow shape, they are capable of
establishing well-described and controlled surface and volumetric shear profiles.
Using suitable scaling and careful experimental design, these systems have been
able to answer geometrically relevant questions, and have greatly enhanced our
fundamental understanding of shear-dependent, thrombotic surface reactions [18,
44, 45].
2.2 THROMBOTIC FINGERPRINTS
As explained earlier, a variety of anti-thrombotic agents and strategies have
become the standard of care in the treatment and prophylaxis of thrombotic events.
At the basis of these strategies is balancing the risk of blood clot and the equally
important risk of major bleed. Due to this, decision-making trees, developed from
the outcomes of numerous studies and professional opinions, have been employed
in clinical scenarios. These empirically-based strategies have been traditionally
based on lumped populations, and only more recently has focus switched to the
interaction of a multitude of genetic and environmental factors which determine an
integrated outcome, generating a highly individualistic record of a patient's
propensity to clot. The need to break down these groups into smaller sub-
populations and individuals has become increasingly recognized.
Many clinical decision are based upon the findings of in vitro models, whose
problems are highlighted by their general inability to represent clinically relevant,
complex in vivo thrombotic scenarios. These current tests are capable of producing a
single output which is then related back to in vivo information, forming a one-to-one
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mapping of data. At the basis of these in vitro tests, though, is powerful factor
isolation, assay activators, and system standardization which skew the outcomes of
these tests, reducing the foresight and ability to predict clinical outcomes that the
experimenters may derive from the test results. Rather than relying on such single
potentially biased values, our approach will ascertain a larger portion of this map
from parametric considerations of qualitative biological factors. We propose that
such an in vitro mapping of relevant parametric space will yield an individual
Thrombotic Fingerprint that should contain novel information of in vivo clinical
relevance that could otherwise not be gained from single-value correlations.
2.3 FLOW SYSTEM EVALUATION
The current list of model flow systems available to researchers and clinicians to
study the process of thrombogenesis and the hemodynamics with respect to it and
to the human condition, was compared against a variety of criteria (Table 1).
Table 1: Comparison of flow system attributes. (Subjective scale that ranges from
+++ - --- , which is equal to Excellent 4 Poor.]
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The tests listed in this table have brought scientists and clinicians great
advancements in the understanding of acute thrombosis. The third major type of
experimental system, the ex vivo model, has provided the bridge necessary to relate
results derived from in vitro and in vivo models [19].
Even with all the models available, inherent problems still remain with the
models' ability to encompass all aspects of the thrombotic process. Newer testing
methods, such as the in vitro accelerating loop system developed by Kumaran
Kolandaivelu [18], have successfully improved upon the weak points of the previous
systems. His system is capable of maintaining a strong control over the in vitro
biological environment, while creating well defined and physiologically relevant
blood flows, as well as maximizing the biological signal output and reducing noise in
the results. Having studied and tested with the rotating loop device, the advantages
and shortcomings of the machine became apparent. The testing system described in
this thesis project solved several of the rotating loop device's problems through the
key criteria of our new machine design. These criteria include:
1) The ability to tightly control and concurrently test a wide number of test
conditions dictated by Virchow's Triad.
2) Utilize small blood sample volumes to perform these tests.
3) Allow for the high volume of test conditions to be run quickly and easily,
while outputting accurate and consistent data.
Briefly, a variety of routes for improvement upon Kolandaivelu's rotating loop
machine design were initially considered. This was followed by the decision to leave
the constraints of the loop design and develop a 384 channel device capable of
varying flow, blood, and vessel wall conditions across all of the blood channels. The
device would allow for simple and safe manipulation of the blood, and would feature
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a reliable and ubiquitous assay method to produce strong and reliable biological
signals. Finally, the device allows for the use of small blood sample volumes per test,
and is cost effective in terms of both capitol and time costs.
2.4 MULTIPLE-PARAMETER
THROMBOSIS
2..1
IN VITRO MODELS OF
PULSATILE LOOP MODEL OF THROMBOSIS
The in vitro pulsatile loop model of coronary lesion thrombosis (by Kumaran
Kolandaivelu) [18], served as the inspiratory and investigatory starting point for our
new in vitro model. At the basis of the thrombotic model is a fluid filled torus which
is rotated about its axis (Figure 5).
Torus
Fluid
Figure 5: Fluid filled torus. A clockwise motion of the torus about its axis causes
clockwise fluid motion relative to the torus wall [18].
When the torus is impulsively moved an inertial fluid motion results in the
opposite direction. Assuming that the torus is quickly spun up from rest to a
constant angular velocity, with time the fluid inside the torus will accelerate to
match the speed of the rotating torus due to a bulk momentum transfer into the
fluid via shear forces. This sort of fluid flow has been analyzed by Lyne, who likened
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the flow in the torus to that of a pressure driven flow, where the acceleration of the
fluid takes on the driving character of a body force [46]. In the case of flow-
dependent thrombotic reactions, the important characteristic of the flow is the
velocity gradient or shear rate, which characterizes the velocity profile of the fluid
when looking at a tube flow from a longitudinal cross-section view [29, 47, 48].
Using this technique, the model would create time-varying flows whose
characteristics would match the flow qualities found in the coronary arteries,
specifically the mean Reynolds, Womersley, and peak Dean parameters (Figure 6).
In addition, the model also took into account the Newtonian approximation for the
kinematic viscosity of blood ( a non-Newtonian fluid) which has been shown to be
valid for high shear conditions (>100 s-1) and is often applied when considering
coronary flow [25, 28, 49, 50].
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Figure 6: The meshed plot surface depicts the axial fluid velocity distributed radially
in the flow tube, as a function of time given a square wave angular velocity input
[18].
The full embodiment of the system includes (Figure 7) a fluid loop, rotor-
stage on which the loops are mounted, driving motor, motor controller, and a
measurement system.
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Figure 7: Schematic of multi-rotor in vitro flow loop model of thrombosis. (Left) Two
rotors with attached flow tubes, mounted upon two motors conencted to supporting
hardware. (Upper right) Photograph of a flow tube with dyed water. Note the blue
flow transducer that returns instantaneous flow data. (Bottom right) Photograph of
flow loop with a reactive section containing a stent. [18]
This embodiment of the rotating loop flow system allows simultaneous
testing of six blood samples via six modular rotor platforms per axis. The blood
samples would be loaded into the flow loops which were coated with a blood-
unreactive protein, such as albumin. A small section of the tubing, labeled the
reactive section, was coated with a reactive species such as one of the constituents
of the subendothelium, and could also contain an expanded and implanted stent.
The rotors set up on the motors were then driven through a desired angular motion
profile by means of a control system on a computer linked to the motor. This bi-
directional spinning motion would create internal flows which were then measured
via onboard flow transducers built into the rotor stage. These transducers would
instantaneously provide information about the flow profile and the rheometry of the
blood.
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PARAMETER VARIATION AND OUTPUT DATA
One of the greatest advantages of this apparatus was its ability to experiment
with a wide span over any of the Virchow's triad derived parameters. Specifically, a
large number of permutations of physiological shear rates, vessel wall coatings, and
hyper/hypocoagulable blood states could be tested. The single output variable
derived from the three input variables was an indication of the amount of
thrombotic burden captured by the reactive section of the flow tube. Assays would
characterize the amount of thrombosis in the test loop by the concentration of
platelets and other bound cells to the reactive segment. This data would be directly
correlated with the thrombogenicity of the particular set of blood and wall states,
and flow conditions experienced in the tube during the test run. This enhanced
experimental resolution would greatly improve upon the limited perspective that
current testing systems have given us about the hemodynamic nature of thrombosis.
2.4.1.2 LIMITATIONS OF THE PULSATILE LOOP MODEL OF
THROMBOSIS
The pulsatile loop model of thrombosis provides a great number of
improvements upon previous assay systems and extended knowledge, for example,
by comparing the thrombogenicities of gold coated versus bare metal stents. This
model also featured some process and mechanical limitations discovered over the
course of building, validating, and testing with the model. Primarily, it was found
that greater use of the data derived from this machine would be derived from a
larger number of tests featuring a wide variation of parameters. Due to the sensitive
nature of blood, tests on blood samples drawn on two different days may not
provide accurate or relevant data, as a variety of environmental or physiological
conditions could affect the thrombogenicity of the blood from one blood draw to
another. Because of this, tests would have to concurrently examine parametric
variations on a single blood draw, necessitating the ability of the thrombosis model
to accept a number of blood, wall, and flow conditions in parallel. The physical
embodiment of the rotating loop model was hindered by its ability to test blood
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samples at a single flow condition, making it very difficult to compare the
thrombotic signal due to variations in flow across tests on different blood samples.
In addition, the machine featured a large amount of user involvement during
the preparation, testing, and assaying steps. To properly and safely prepare the
machine for a run, a team of at least two individuals would have to carefully load the
blood into the tubes, while removing all entrapped air. Each flow loop required at
least a full minute to fill with blood and ensure the escape of air. This process alone
injected a considerable degree of error into the testing process due to the inability
to fill all the tubes at the same time, such that a staggered order of tube filling would
have to be compensated for. The human factor concerning the interaction with
needles, syringes, and blood made the situation impossible to speed up, and greatly
increased the biological hazard of blood contact.
Finally, from a point of view of future expansion, the machine lacked the
ability to grow with the increasing test volume needs as investigations developed.
Each flow loop required a 3mL blood sample, requiring large samples of blood to be
drawn from volunteers or animals when testing a variety of conditions with several
repeats. Also, the design of the machine required increased user interaction with
each increase in test volume. Adding more rotors to accept more blood samples
would quickly reach a limit defined by the users' abilities to quickly and properly
load the samples into the tubes, test, and assay the results. As an investigation on
the nature of thrombosis develops, an increased number of tests covering a wider
parametric scale would be required. Eventually, a solution would be needed that
greatly reduces the blood volume per test while increasing the parametric variation
and resolution featured in concurrent tests.
2.4.2 RATIONALE FOR NEW FLOW MODEL PURSUIT
Consideration of the process and design limitations of the rotating loop flow
model led to a list of the basic constraints and goal parameters to guide us in
developing an improved flow model. In reaction to the previous design, it was
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determined that the number one priority of this design was to concurrently test one
or more variables, while also performing repeats of each testing condition to ensure
precision. Secondly, the sample of human or animal blood required for each test
needed to be decreased considerably. It was understood that the nature of this
thrombotic testing would eventually lead to high volumes of tests brought about by
exponential test number growth from parametric variation along three axes. The
final major design goal was to integrate a commonly found and easy to use lab and
clinical blood collection and assay system into the design from the outset. This
element would ensure a minimum of noise from preparatory processes and human
error, while maintaining hygienic conditions and adaptability to the clinical
environment.
Two high-throughput flow models were proposed: a rotating well flow model
and a linear flow model. The rotational flow model was the most directly derived
from the pulsatile loop model, incorporating the principle of utilizing the inertia of a
stagnant fluid as a means of developing motion relative to the container walls by
imparting a spinning force on the container. Briefly, a container resembling a 96-
well or 384-well plate would be pre-treated, then filled with blood samples and
covered with a lid. The plate would then be centered on a turntable. Combinations of
well dimensions and turntable spinning programs would be used to develop well
controlled fluid shears in each well.
The linear flow model involved a one-pass system whereby 384 glass
capillaries would allow blood to flow down a pressure gradient from one blood
collection receptacle to another. All of the flow routes would feature a section of
identical dimensions, followed up by a section featuring custom dimensions that
would allow flow rate variation. The glass capillaries of the flow system would also
be designed to mate with a standard 384-well plate to incorporate standard
assaying systems into the protocol.
The initial determination of the feasibility of these concepts was based on the
theoretical fluid mechanical models that would inform us about the rotation rates,
pressures, dimensions, and sample sizes necessary to create the desired model flow
profiles.
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CHAPTER 3: FLOW MODEL DESIGN
3.1 ROTATING WELL FLOW MODEL
3.1.1 DESCRIPTION OF SITUATION
The rotating well flow model was a high throughput evolution of the flow
model developed by Kolandaivelu [18]. A fluid filled container was accelerated
about its axis of symmetry to create wall motion in relation to the fluid, whose
angular speed lagged behind that of the wall because of its own inertia. The relation
between the wall and fluid's rotational velocity became the wall shear rate, which is
of interest to us in our flow model. With the use of periodic accelerations and
decelerations, one could ideally maintain a particular shear rate in a fluid filled
container. In this particular model, the containers that held the fluid were of
dimensions equal to the wells of a 96-well plate and were arranged radially on a
circular disk that was spun from its center. The advantage of this configuration was
that it potentially allowed for the easy loading and testing of many samples of blood,
as well as it would allow for an easier assay of the samples to obtain a great deal of
data per test run.
3.1.2 ROTATING BUCKET EXAMPLE
The rotating bucket is a classic name given to the situation where a closed
cylindrical fluid filled cavity is spun up from a standstill. The analysis of this type of
system is much easier when assumptions such as the fluid being in rigid body
rotation or an infinitely long cylinder, can be made. This approximation, though,
must be carefully applied to a finite length situation (especially if the aspect ratio is
low), as experimental results may vary greatly from the theoretical results. For a
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liquid of low viscosity, a relatively long time is required for the liquid to rotate as a
solid body, and even during this transitional period, the fluid flow may become
unstable [51]. The reason that an assumption that the cylinder is infinitely long is
difficult to make is because it has been found that the effects of cylinder ends on the
fluid motion can actually dominate the flow, even in very slender cylinders. This
fluid motion is affected by a secondary flow caused by the cylinder ends in a region
called the Ekman layer, which convects the fluid from the walls to the interior of the
cylinder. As a result, the fluid attains rotational velocity much more quickly than
without these secondary flows (Figure 8).
Secodary cirulation
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Figure 8: Rotating bucket flow profile. Note the secondary circulation caused by the
Ekman layer.
3.1.3 EQUATIONS AND SOLUTIONS
In the particular case of rotationally symmetric flow, with small radial and
axial secondary flow in the interior, Greenspan [52] explains that the azimuthal fluid
spin-up is governed by:
-+u -+ =V[aQ +- E 1at ( r r ar 2 arrEq1
where u is the radial velocity, v is the azimuthal velocity, and r is the well radius.
This can then be solved by
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u =-K v 2(rQ -v), Eq. 2
where f2 is the angular velocity and h is the height of the cylindrical well. Greenspan
explained that when K=1, Equation 2 becomes identical to the corresponding
equation for linear spin up. In addition, he made several substitutions into the
resulting equation:
r v t(vQ)",=2  a v
R=-,V= J= ,]'-E=
a aQ h h fh 2
- Eq. 3
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In the previous equation, a is the radial distance from the center of the well, A
is the aspect ratio, E is the Ekman number, and the portion A-2 / 2 can be substituted
with co. In their paper, Watkins and Hussey [53] explained that depending on the
size of ao, the equation can be solved in different manners. A small ao indicates that
the system response to the rotation of the cylinder is very much dependent on the
Ekman layer. On the other hand, if ao is large, it indicates that the response of the
fluid to the acceleration of its container is mostly, to completely, dependent on
viscous effects from the cylinder wall. There is also the regime of ao that falls in
between both extremes and considers a combination of the two effects.
Unfortunately, of the three regimes only the small ao has been studied extensively,
while only very rough solutions have been found for the rest. In this model we only
want to deal with viscous effects, to avoid secondary flows in the well. In the case
that ao is large, its solution is found in the form:
V =R +2L "R) ex n 2 Vt , Eq.4j JO (in_ a
where Ji is the Bessel function of the first kind of order I and jn is the nth zero of Ii.
This equation was solved with the use of the program Excel for a variety of
conditions. The extreme conditions, especially the maximum shear rates that we
wanted to test, were focused on to determine the feasibility of this type of
apparatus. While determining the parameters necessary to create the maximum
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shear rates, it was necessary to take note of the well radius, the maximum rotational
speed reached by the spinning platform, ao, the centrifugal acceleration experienced
by the fluid in the well, the volume of blood in the well, and the time for the fluid to
reach a state of solid body rotation. The results of experimenting with the upper
limit conditions revealed the results presented in Table 2.
Table 2: Results of solving E uation 4 for extreme Marameters.
Shear Rate R, Ti Max Well o Centrifugal Acceleration Blood
3980.47 0.5 0.15 9300.00 0.012 968.69 0.98
4007.53 2 10.0 3780.00 0.001 160.03 15.0
We expound the conditions necessary to produce the upper shear rate design
limit, which was 4000s-1 (Table 2); as confirming whether the apparatus is capable
of these limits determines the feasibility of the device. The largest difference
between the two cases presented in the table is found in the radius of the well
(Rweii), where one well is about the size of a well in a 96 well plate, while the other is
much larger to provide a good contrast. The advantages of a small well can be seen
in this table. The small well requires a much smaller blood volume, allowing for
nearly 60 experiments to be run from a typical blood sample, which is generally
about 60mL. The larger volume would only allow about 4 tests to be taken. Also, the
smaller well requires much less time for the fluid in the well to achieve a state of
solid body rotation, because of viscous effects and its greater surface area to volume
ratio. This ratio is important when considering that the cylinder would have to cycle
through acceleration and deceleration phases in order to continually create the
shear rates required by the test. The dependent variable, Tsolid body rotation, indicates
the time delay between the moment that the well achieves its final rotational speed,
and the moment that the fluid in the well reaches the rotational speed of its
container's walls. A Tsolid body rotation of 0.15s is much easier to work with than one of
10.0s, which would take up a great amount of time considering that each test would
only run between 1-2 minutes. Advantages to using a larger well volume include the
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need to accelerate the cylinder to a considerably lower final rotation rate to achieve
comparable shear rates, and therefore lower centrifugal accelerations on the
samples are also expected. In theory, this system should reach its maximum
rotational speed in less than 0.1s.
Outside of the advantages of one well size over another, the table provides
information that indicates this testing method would not be feasible. To meet the
goal shear rates of around 4000 s-1, high rotation rates must be reached by the
motors running the experiment. These rotation rates will then cause great
centrifugal accelerations in each well, which quickly approach blood separation
values as one increases the distance between the center of the plate and the well. As
a rule of thumb, blood centrifuged at rates between 300-500 G's begins to separate
between plasma and cells after only a few minutes. The generation of this effect
would be very detrimental to the results of this experiment. In addition, the value of
ao becomes very small at these rotational rates, which indicates that this system
should actually be solved using the small ao approximations of Equation 3.
Moreover, the fact that this system has a small ao denotes that the rotation of the
fluid is very dependent on the Ekman layer, which in turn means that the fluid
rotation is greatly influenced by secondary flows present. These secondary flows
would be very detrimental in the simulation of the simplified physiological
environment that this model is aiming to create, and needs to be avoided as much as
possible.
Finally, during the research that was completed for this model, it was found
that "spin down" or the deceleration of the fluid inside a sealed cylinder, was not
symmetric to "spin up," or the acceleration of the fluid [54]. Spin down can occur in
an impulsive or finite manner. During an impulsive spin down the fluid particles
near the cylindrical wall will rapidly experience a centrifugal instability. This
centrifugal instability can lead to the creation of "Taylor Gortler" vortices along the
side wall [55]. As spin down proceeds, the smaller vortices coalesce into larger ones,
generating a much more rapid spin down than what would be predicted by
nonlinear theoretical arguments. This problem can be delayed by conducting spin
down over a finite period of time. The problem may even be completely avoided in
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the slowest deceleration conditions, but the problem with this solution is clear in
this test. The time needed to decelerate, and/or change the rotation direction of the
fluid is of great importance, and a great deal of time cannot be applied towards
deceleration of the fluid.
The combination of all of these technical difficulties led to the decision to explore
the feasibility and design of a high throughput, one-pass linear flow device.
3.2 LINEAR FLOW MODEL
3.2.1 DESCRIPTION OF SITUATION
To create the desired flow profiles, and therefore, the desired wall shear
rates, a fluid flow was generated down the length of the flow tube by a pressure
drop, creating a Poiseuille flow (Figure 9). The difference between the pressures at
the entrance and exit of the tube allowed for fluid to be moved from its initial
container to a final collection reservoir. The wall shear rate in the tube was
determined by the profile of the flow, which in turn was a factor of the tube
dimensions as well as the fluid flow rate. Given a particular pressure drop and
volumetric flow rate, the flow's velocity was controlled by varying the cross-
sectional area inside a tube. In the case of flow-dependent thrombotic reactions, the
maintenance of velocity gradients or shear rates was the important flow factor.
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Figure 9: Parabolic flow profile generated by Poiseuille flow conditions (pressure
gradient down flow channel) [18].
Using this technique, we hope to initially create time-invariant flows, whose
flow characteristics such as the dimensionless flow parameter Reynolds (Re) and
wall-fluid shear rate were typical of physiological blood flows found in arteries. The
theoretical model developed for this apparatus represents a straight pipe composed
of three sections: the test section, the contraction, and the resistance section.
(Figure 10).
Contraction
'
Testing Section Resistance Section
Figure 10: Cross-sectional sketch of the theoretical straight pipe model.
The test length section of the model has constant parameters across all
testing conditions. The contraction and resistance sections will vary to modulate the
shear rate conditions of a test.
3.2.2 EQUATIONS
The most important parameter of the fluid flow in this model was the shear
rate experienced between the fluid and the wall. This information could be found by
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solving only the axial (z) component of velocity of the cylindrical form of the Navier-
Stokes equations (Equation 5)
av, avvsav v, P 8 v, 1 a2V, + 2Vp 'j ++v -L j + = p -- I + +] Eq. 5
( ct a r r t90 az az r ar ar r'282 z
where Vz, Vr, and Vo are the velocity components in the axial (z), radial (r), and
tangential (0) directions, respectively. Also, t is time, p is the fluid density, and 6P/6z
is the axial pressure gradient. In the case of our specific model with its
circumferential and axial symmetry, Equation 5 was simplified through the
elimination of several dependencies. This was then integrated to give
V. = + dr2±+1r+ 2 Eq. 6
2 p dz pU p
Equation 6 provided the velocity profile of the flow. Inputting the boundary
conditions of this system (at r = Rtube, Vz = 0, and at r = 0, dVz/dr = 0) gave us
1 (dP 2  1 (dP 2~V- = 'r 2_I(pR 2Eq. 7
2 dz 2 p dz
Taking the derivative of this function with respect to radial distance yielded a
function for the shear rate of the flow.
a V- I dP)
=- -- r Eq.8
ar p dz)
Finally, inputting a radial distance of half the tube diameter into this formula gave us
the fluid's shear rate against the wall.
av. 1 (dP
=- -- K)R Eq.9
cBr p (dz
To determine the flow profile and the wall shear rate, it was necessary to calculate
the pressure head loss across a certain piping distance (major head loss), which was
found with the use of the Darcy-Weisbach equation:
64 (L pv2~AP =6 -(L Eq. 10
Re D 2
Equation 10 was used to determine the head loss across the testing and resistance
lengths of the tubing. The head loss associated with the tube contraction could then
be found with
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AP=-pV2L1 2 j, Eq. 11.
4 , I Di
where V is the linear velocity of the fluid, and Di and D2 are the diameters of the
tubing before and after the contraction, respectively.
Finally, the total head loss was equated to the sum of the losses incurred by
each of the tubing sections. The length or diameter measurements of each resistance
section were then modified until the head loss equaled the difference between the
input and exit pressures of the tube. The difference between the input and exit
pressures of the tube were set by using Equation 10 to determine the pressure drop
necessary to move blood through a simplified model of the tubing at a shear rate of
4000 s-1 (the maximum shear rate to be tested). The parameters for the tubing
included a diameter equal to that of the test section and a total length equal to the
test and resistance sections combined.
3.2.3 SOLUTIONS
Using the linear straight tube approximation, the necessary pressure drop to
move blood at a shear rate of 4000 s-1, was equal to 56.5 KPa. Using this figure, it
was then possible to determine the dimensions of the tube sections. All the
calculations involved the test sections of one size, which were chosen such that we
could meet our targeted volumetric flow rate goals while allowing for a large
enough volume for a good assay signal, which was 7.5 ptL. Only the dimensions of the
resistance section changed according to the different shear rates. The dimensions of
the test section are found in Table 3.
Table 3: Dimensions of the test section of the tubing.
Internal Diameter 0.03 cm
Cross-setonal Area 7.06 x 10- cm 2
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To ensure that the thrombotic signal from the test portion of the tubing was purely
due to the predictable shears of a laminar flow, the Reynolds number in the test
section had to be examined (Figure 11).
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Figure 11: Reynolds number of the flow in the testing section as a function of the
shear rate.
The very low Reynolds numbers experienced at our planned shear rates
ensure that the flow conditions will be dominated by viscous fluid interactions and
not inertial interactions. This guarantees that the flow will be laminar and therefore
the mechanical interactions between the blood and wall will be predictable.
For the dimensions of the resistance section tubing, a choice had to be made
about whether to modulate the flow resistance by varying the lengths or the
diameters of the resistance sections. Variation of length was first investigated, but it
was quickly found that the length of the longest tube would be over 80 times the
length of the shortest tube which would bring about problems with the actual
manufacture and design of the apparatus. Variation of the tube's inner diameter
would require variation between 90 microns and 300 microns, which are well
within the capabilities of modern glass capillary tube manufacturing.
Before determining the final dimensions of the resistance pieces, it was also
necessary to compensate for the Fahrous-Lindqvist effect experienced by blood, a
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non-Newtonian fluid. This property of blood causes it to send most of its red blood
cell content to the center of a flow tube as a means of exposing a greater part of its
platelets to the periphery. As a result, the true fluid viscosity experienced at the
conduit wall becomes a function of the inner diameter of the channel (Figure 12).
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Figure 12: (Left) Stretching of red blood cells due to increased flow shear
(Right) Plot of the relative viscosity of blood as a function of tube diameter.
Due to this effect, the resulting viscosity of the blood due to the Fahrous-Lindqvist
effect had to be accounted for in calculations (Figure 13).
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Figure 13: Inner diameter of resistance section of the tubing as a function of the
intended shear rate for the channel. Note the small size difference between the
calculations that compensate for the Fahrmus-Lindqvist effect, and those that do not.
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The dimensions of the resistance section tubing are found in Table 4 (the Matlab
code written to calculate these results is found in Appendix A).
Table 4: Dimensions of the resistance section of the tubing.
100 17 0.0101 8.01185E-05
200 17 0.0121 0.00011499
500 17 0.0155 0.000188692
750 17 0.0174 0.000237787
1000 17 0.0188 0.000277591
2000 17 0.0233 0.000426385
4000 17 0.0300 0.000706858
In addition, it was found that the head loss due to the tubing contraction
(minor head loss) was very small in comparison to the major head loss, so that the
manner in which the tubing contracts (gradual vs. sudden) matters little in this case.
With the application of a specific pressure drop, we could then control the
volumetric flow rate, and therefore, the wall shear rate in the tubing.
3.2.4 TESTING PROTOCOL
Once the means by which blood flow control through our thrombosis model
with minimal disturbance was established, the testing protocol, and more
specifically, the assay process had to be determined. The linear flow one-pass
framework of the model allowed it to readily adopt a very systematic assay method,
where the operator of the machine would interfere little with the concurrent
processing of a large number of test samples. Borrowing much of the assay method
utilized in the rotating loop model of thrombosis, the hardware and processes
necessary to support the linear flow system were evolutions of the systems used in
the past model.
The testing protocol involves five steps:
Step 1 - Coating of the system's reactive section with one or more
subendothelial components, such as collagen, fibrinogen, or von Willebrand
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Factor. This constitutes the wall condition axis of Virchow's Triad. The
reactive section of the linear flow system is the testing segment of the
channel (Figure 10).
Step 2 - Treatment of the blood pre/post drawing from the patient, prior to
loading into the flow machine. The blood may be treated with pro/anti-
platelet or pro/anti-coagulation drugs. This constitutes the pro/anti-
thrombotic blood condition axis of Virchow's Triad.
Step 3 - The blood is then channeled through the reactive section (test
section) at the prescribed shear rate for a specific amount of time. This step
represents the last axis of Virchow's Triad, flow conditions.
Step 4 - After the blood is run, is it cleared from the tubing and any loosely
bound blood components are washed away by a buffer solution (Tyrodes
buffer with added MgCl and HEPES).
Step 5 - The blood components that remain bound to the test section must
be quantified. This is done by lysing the bound platelets to release their
internal components, specifically lactose dehydrogenase (LDH), a substance
commonly assayed for when searching for signs of cell damage. The LDH
released from the bound cells are contained in solution, which is then
colorimetrically assayed by means of a spectrophotometer, to directly
quantify the bound cell density of the test section.
The next steps involved incorporating the steps of the test protocol and the means
of creating the low-disturbance Poiseuille blood flow, into a machine that bridge the
ideas of biological testing and assaying with high-throughput mechanical
advantages to develop the Thrombotic Fingerprint.
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3.3 EMBODIMENT
The linear flow model was developed directly from the tubing schematic
(Figure 10). Initially, it was understood that a means of securing a matrix of glass
capillary tubes composed of a uniform testing segment and a variable size resistance
section, was the foundation of this machine. After the design of these components
was finalized, the supporting hardware which would help load and dispose of blood
samples as well as assist with the signal assay steps, was developed. The
embodiment of all these concepts kept in mind the need to maintain hygienic
conditions, ease of use, protection of fragile components, repeatability, and low
usage costs. The following sections describe the evolution of the major system
components and their final revisions.
3.3.1 TEST BLOCK
The test block serves as a means of fixing flow channels containing the
reactive section of the tubing in a fixed and specific matrix conformation, so that
they may be tested upon and controlled in unison and so that the fragile glass
channels may be kept safe. In the first iteration of the test block's design (Figure 14)
a 3x8 matrix of capillary tubes was encapsulated in a rectangular block along with 4
hollow plastic tubes that allowed the block to be aligned on a platform.
Figure 14: Photograph of the top of the first test block design iteration.
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The creation of the first test block brought into mind several considerations
into the block's design. First, it was found that a transparent silicone rubber would
prove useful to view whether liquid was entering a particular tube, as well as inform
the user about any defects or damages to the glass capillaries. Next, the elastic used
to form the block was sufficiently protective for the tubes, but perhaps of too low a
stiffness to provide proper alignment when mating the tube ends to another set of
tubes. A different material or an internal structure to form a more rigid block was
necessary. Third, any manipulations near the protruding male ends of the tubing
were potentially dangerous, in that they could easily be broken. Therefore, any part
in contact with this face of the block needed to have accuracy and clearance to
account for these protrusions, to allow for any procedures involving this area to
ensue without hitch. Finally, it was observed that as a product of the sheer number
of connections between the testing and resistance blocks, it may be difficult to
separate the connected blocks without possibly harming the tubes.
The first two problems were solved by finding a suitable silicone rubber. The
Sylgard 184 silicone rubber was chosen due to its combination of long working time,
high transparency, and a stiff enough constitution to provide proper protection for
the glass while allowing for accurate positioning of the glass tubing. In addition, the
material was also suitable for biological experiments where it would come into
contact with blood, and had to be able to withstand several autoclave cycles.
The tube alignment problem was partially solved with the use of the new
silicone material. Initially, a set of rigid metal rods spanning the length of the block
was suggested as a means of increasing the stiffness of the block and the alignment
of the tubes. Later, it was determined that a mold properly designed for the block
that would carefully secure the glass tubes in the material at the proper matrix
spacing, would ensure correct tube alignment. The final design issue dealt with the
difficulty one may have disjoining a number of test blocks mated with a set of
resistance blocks. A solution to this situation involved linking the various test blocks
by means of metal rods threaded through them (Figure 16).
The current iteration of the test block (Figure 15) features an 8x3 matrix of
glass capillary tubing. The borosilicate glass tubing is manufactured by Vitrocom
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Inc. and features a 10cm length, 1.27+0.005mm OD, and a 0.300+0.005mm ID. The
spacing between the tubes is specifically measured to mate directly to a 384-well
plate. The layout of the block is intended to perform concurrent testing of 3 repeats
of 8 different shear rate conditions. The ends of the tubes extend from the bottom
surface of the block to reach into the 384-well where it deposits the biological
solution to be assayed. The tubes also extend from the top surface to mate with the
resistance block which will sit atop the test block. The test block also features two
holes in the center of the block, that cross its thickness and are used to mount a 8x2
set of the test blocks on metal rods, in the final machine design (Figure 16, Appendix
B).
SCALE4:1
A
Figure 15: (Left) Schematic of a single test block viewed from various angles. Note
detail A shows a step used to create a vacuum sealing lip against the supporting
hardware. (Right) Photograph of a completed test block.
Figure 16: 8x2 array of test blocks. The footprint of this array can mate directly to a
standard 384-well plate.
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The mold developed to cast the test block is pictured in Figure 17. A drawing
of the test block mold annotated with measurements is available in Appendix B.
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Figure 17: Schematic of the test block mold viewed from several angles. Note that the
front cover of the mold is not shown in order to show the mold interior. (Right)
Photograph of the completed test mold.
The test block mold allows the capillary tubes to span the length of the block
while properly spaced out. The tubes are first installed into the mold, then the mold
is closed and silicone rubber is injected through one of the port holes using positive
pressure. Next the port holes are closed, and the block is cured in an incubator at
50-600C for a period of 4 hours. Finally, the block is carefully removed from the
mold, and any debris that may have settled in the tubes is cleared out.
3.2.2 RESISTANCE BLOCK
The resistance block (Figure 18, Appendix B) was designed very similar to
the test block. The block consists of a 24x16 matrix of tubing encapsulated in
silicone rubber. Unlike the capillary tubing in the test block, the resistance block
contains two concentric tubes. The outer tube which is encapsulated in the silicone
rubber in a mold is made of PTFE and has the dimensions of 17cm length, 3mm OD,
and 1.27mm ID. Inside resides a borosilicate glass capillary tube with the
dimensions of 17cm length, 1.27mm OD, and an ID specific to the shear rate desired
in the channel (Table 4, pg. 44).
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DETAILA
SCALE 4:1
Figure 18: Schematic of the resistance block shown from several angles.
The resistance block sits atop the array of test blocks, and the glass tubes that
extend from the top surface of the test block mate with the resistance tubes at the
bottom surface of the resistance block. The means by which the tubes mate has
undergone evolution. Initially the female end of the resistance tube was designed to
have a conical entrance to assist the male ends of the test tubes to mate more easily.
It was next decided that the guiding mechanism would be built into the rubber of
the block instead of the glass/plastic tubing, due to the difficulty of working with
these materials on such small proportions (Figure 19).
Figure 19: Design feature in resistance block that helps to guide test tubes into the
resistance tubes. A conical entrance is molded into the bottom face of the resistance
block and help guide test tubes from the test block in the direction of the arrows,
until the tubes can mate with the resistance tubes (colored blue in this schematic).
The top of the resistance block will mate with a supporting piece of hardware
that will provide the vacuum necessary to create the pressure drop to actuate the
soChapter 3
blood flow. The tubes extend from the top surface of the block so that blood may
flow out of the tubing and fall from the tubing end into a collection basin, from
which the blood would be removed. This would help avoid any extra resistance due
to blood pooling or clotting outside of, but above, the tube ends. Sections 3.2.5 and
3.2.6 explain the supporting structure of the test and resistance blocks, which
greatly helps in the process of alignment of the tube ends.
3.2.3 BLOOD LOADER
The blood loader (Figure 20, Appendix B) is the first of the supporting pieces
of hardware which are built to accommodate the test and resistance pieces. This
polycarbonate piece enables the operator of the machine to take blood collected in a
standard Vacutainer ® tube, connect it to the machine, and allow the supply of
blood to feed the 24 channels of a test block when the vacuum has been applied. The
blood loader has an 8x2 arrangement of wells, each of which mated to the bottom of
a test block. The wells feature a 1mm step that matches the step cast into the bottom
of the test block, which allows for a more secure airtight seal. This airtight seal
would be very important, as any small leaks would cause unbalanced flows through
the channels and could also inject air into the system, causing premature activation
of thrombotic blood components.
* * * *DETAILB
Figure 20: Schematic of the blood loader, viewed from various angles. (Right) A side
view of the part showing hidden lines. Note that Detail B shows how channels
connect the test block well to a port that connects to a Vacutainer.
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Each one of the 16 wells of the blood loader feature a channel that connects
the well to a supply of blood in a Vacutainer@ (Figure 21). The connection to the
Vacutainer is made through a needle fastened to a port of the channel. The blood
loader must form a tight seal with the test block component which rests on it, but
must also be quickly, safely, and easily removed from the test block during the
testing process to perform the subsequent washing and assaying steps. To
incorporate quicker transitions between testing stages, a site to secure a standard
384-well plate was machined into the blood loader.
Figure 21: (Left) Blood hopper with attached Vacutainer tubes. (Right) Blood hopper
with secured 384-well plate during assaying steps.
Finally, it was understood that not every test performed on this machine
would involve 16 separate blood samples with their respective test blocks.
Therefore the option to run a less than full load of test blocks during a particular test
had to be made available. This would be completed by creating blank test blocks
made of solid silicone rubber containing no glass tubes inside them. These blocks
would allow no flow through their respective resistance tubes and wells in the blood
loader. Therefore, vacuum pressure would only be applied to the channels of
interest, allowing for testing of even just a single Vacutainer@ collected sample.
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3.2.4 VACUUM CONNECTION
The vacuum connection (Figure 22, Appendix B) is the second major piece of
supporting hardware for the flow system. This polycarbonate component is
designed to mate to the tops of both the resistance block and the 8x2 arrangement
of test blocks, and provide the negative vacuum pressure to create a pressure
gradient down the flow channels and actuate the flow of blood. As explained in the
previous section, the flow of blood will begin from the enclosed Vacutainer@
reservoir, and end in the vacuum chamber which encloses the protruding ends of
the resistance tubes. The component also features side ports to allow for the pooled
blood to be collected and discarded properly, and to allow for the injection of buffer
into the vacuum chamber to assist in the removal of the blood.
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Figure 22: Schematic of the vacuum connection viewed from various angles. (Left)
Note that the component is pictured upside-down in order to show its internal
compartment. The part also features built-in mounting components which will be
described in the following section. (Right) Top and side angle views of the
component showing hidden lines. Note the side ports used to remove blood, and the
port through the top used to provide the negative vacuum pressure.
The first iteration of the vacuum connection design featured a number of
tapped holes in the top of the chamber interior which provided a stable base for a
number of rods that would pass through and correctly align the test and resistance
blocks. This idea was improved upon with a new structure and mounting system
described in the next section. The top dimensions of the resistance block and the
array of test blocks are identical to mate properly with the vacuum connection. The
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vacuum connection also features a lip which fits over the top edge of the resistance
and test blocks, to enhance the air-tight seal. The vacuum connection would be
utilized during several phases of the testing process. During the blood run, the part
would mate to the resistance block to actuate the blood flow, and safely collect the
used blood. Next, during the tube buffer wash, the vacuum connection is mated to
the top of the test block array to actuate the flow of buffer, and safely discard all the
fluid. Finally, during the assaying phase, the component will remain connected to
the test block array to suck the cell lysing solution into the channels and then to
expel the solution into their respective wells in a 384-well plate.
3.2.5 COMPLETE APPARATUS
The complete testing apparatus (Figure 23) was built around the test and
resistance blocks to facilitate the loading of blood, the buffer washing process, and
the assaying of the biological signal held
within the test tubes. The vertical layout
of the apparatus takes advantage of
Dgravitational effect on the fluids used in
the system, such as the gravitational
pressure head in a column of fluid, and
the auto-leveling of a fluidic surface,
that are extremely helpful in the
controlled loading of fluid into the
device. The machine's layout also allows
for quick and easy transitions between
phases of the testing process by simply c
sliding one component out of the
system, and sliding another one in its
place. The problems associated with
proper alignment of components is Figure 23: Picture of the complete
apparatus containing the array of 16
test blocks (A), resistance block(B),
blood loader (C), and the vacuum
Chapter 3 connection (D) as well as all mounting
components.
solved with the use of four 0.5" precision hardened guide rails paired with precision
linear ball bearings on all the components.
The test blocks and resistance block are each mounted on a set of precision
linear ball bearings by means of a mounting sleeve mated with the structural step
designed into the rubber body of the test and resistance blocks. During the blood
run phase of testing, components A, B, C, and D are all mated (Figure 23). In
addition, the top of the vacuum connection is attached to an electronic pressure
regulator to provide the necessary pressure head to actuate the flow. The sides of
the vacuum connection are attached to two syringe pumps, one of which infuses the
vacuum cavity with buffer to wash out the blood, the other pump collects the pooled
blood over the period of the run in a syringe for easy disposal. The next test phase,
the buffer wash, involves removal of component B from the system, the
disconnection of components A and C, and the connection of component A to D. An
open top container full of a Tyrodes buffer with added MgCl (10 mMol) and HEPES
(0.75 mMol) is placed under component A, and the vacuum pressure is applied once
again to allow for buffer to run through the channels at a specified shear rate for a
specified time period. The final test phase involves placing a 384-well plate in its
designated spot on component C, filling its wells with a lysing solution, and bringing
down components A and D to mate with the plate. A particular negative vacuum
pressure will then be applied such that the lysing solution may rise to the tops of the
channels without spilling over, and the fluid is incubated for a prescribed amount of
time. Finally, the fluid is expelled from the channels back into their respective wells,
and the solution is assayed colorimetrically.
3.2.6 SCALED DOWN FLOW MODEL
After designing the high-throughput flow model, it was decided that
validation of a variety of the mechanics, designs, and processes would be necessary
before manufacturing the full-scale 384-channel flow model (Figure 24, Figure 25,
Appendix B). To perform the validation testing a 24-channel system was developed
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by scaling down many of the components of the 384-channel system. A single test
block with up to 24 channels would be tested with the help of a scaled-down
resistance block, and reduced size versions of the vacuum connection and blood
loader components.
Figure 24: (Left) Schematic views of the vacuum connection (top) and the blood
loader (bottom) for the 24-channel, single test block flow model. (Right)
Photographs of the manufactured components. Note the extra views from different
angles showing hidden lines to the right of the three-dimensional part views.
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Figure 25: (Left) Schematic of the individual resistance block which is mated to a
single test block with up to 24 flow channels. Three views from different angles are
shown, the front and side view show the hidden lines. (Right) The mold used to
create the individual resistance block. Three views from different angles are shown.
The reduced vacuum connection features an interior lip to form a tight seal
around the top of both the individual test block and the individual resistance block.
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The vacuum connection also contains a port to connect to a regulated wall vacuum
source, as well as a pair of side ports that connect to syringe pumps to help remove
blood or buffer that pools in the chamber during a test run. The blood loader
features dimensions and an internal lip that allows for a secure air-tight seal with
the bottom of the test block. A channel that leads up to the blood loading well (as
shown in Figure 24) carries blood from a Vacutainer@ reservoir, through a needle,
to the glass channels. The individual resistance block is the test mule for a new way
of casting the test and resistance blocks. Instead of casting the fragile glass tubes
directly into the rubber, an extremely time-consuming process for even a skilled
operator, PTFE tubes are cast into the rubber. Once the block is removed from the
mold, the glass tubes are passed into the PTFE tubes, and secured in place with a
small amount of epoxy. In addition, the resistance block features a conical entrance
into the tubes from the bottom end of the block, which facilitates the mating of the
test and resistance blocks.
A mounting system was designed for these components, and a vertical
organization similar to that of the full-scale system was developed (Figure 26).
Figure 26: (Left) Schematic of the 24-channel, single test block testing setup. Note
that a 384-well plate is below the test block, although the blood loader may also be
placed below the test block. (Right) Photograph of manufactured test setup.
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Validation testing upon this 24-channel setup should provide several
advantages over immediately proceeding to the full-scale 384-channel testing. First,
the high cost of manufacturing prototype equipment suggests that all potential
design issues should be discovered and solved with the use of smaller scale
equipment which maintains most or all of the problems and drawbacks of the full-
scale system. Second, a close focus over individual components and even the
features of individual components will improve our ability to track down the
sources of problems to fix them more effectively. Finally, initial blood testing on this
system will allow us to calibrate the thrombotic fingerprint signal to provide the
most important portion of the data by scaling our investigational resolution around
the parametric regions that provide the most interesting data. The next chapter will
describe the theory, design, and procedural validation testing performed on the 24-
channel setup in greater detail.
The system described allows a steady Poiseuille flow to be produced in the
flow channels. The manner in which the flow is actuated is atraumatic, allowing for
delicate processes like such as thrombosis to be studied in a low noise setting, even
at high shear rates. The system minimizes the entire fluid contact surface between
the sample blood reservoir and the used blood collection area. Also, the flow model
design helps to streamline the testing process while maintaining hygienic conditions
and ensuring user safety, to support the high-throughput nature of the study driven
by the model. By readily allowing changes in flow shear rates, wall conditions, and
blood pro/anti-thrombotic conditions, the system allows for the thorough, multi-
parametric investigation of the biological and hemodynamic processes of
thrombosis.
While the current embodiment has stood a great deal of validation testing (as
will be explained in the next chapter) before finalizing the design to perform clinical
testing, a number of potential system extensions and modifications have been
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brought to light, and may be instituted in the future. These potential extensions of
the system's applicability include the addition of pulsatile flow actuation, as well as
mechanization and automation of many of the tests processes. Each of these
modifications would require reconsidering the current embodiment's design, and
would most likely be undertaken only after the current embodiment has reached the
level of reliable clinical testing.
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CHAPTER 4: FLOW SYSTEM CHARACTERIZATION
TESTING - INITIAL VALIDATION OF HIGH-
THROUGHPUT LINEAR FLOW MODEL
4.1 BIOLOGICAL CHARACTERIZATION
Following theoretical component design, we performed an initial assessment
of the model's ability to study vascular thrombosis. The first testing was performed
on a 12-channel model which investigated simple parametric variation along
Virchow's Triad and the resulting thrombotic signal. Next, validation of the use of
capillary tubes to acquire a strong and repeatable biological signal was performed.
4.1.1 COLLAGEN COATING CAPILLARY TUBES
As explained in Chapter 3, each channel of the flow model contains a test
section that captures the thrombotic signal, and the resistance section, which
modulates the shear rate experienced in each test section. The coating of the test
section, which constitutes the reactive segment of the channel, fulfills the wall
conditions axis of Virchow's Triad. The subendothelium is composed of a number of
cell components, as well as structural and enzymatic proteins, which all play an
essential role in maintaining vessel health and repair processes like thrombosis.
Coating of the test section with one of more of these reactive species simulates
blood flow past the exposed subendothelium after a vascular injury has occurred.
Some of the proposed coatings for the test section include collagen, fibrinogen, von
Willebrand Factor, tissue factor, or any combination of these components. Since the
resistance tubes are to remain unreactive with the blood, they will be coated with
albumin. The quality and strength of the signal derived from the testing sections is
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directly related to the homogeneity and manner in which these components coat the
inner surface of the capillary tubes.
The test tubes are coated by drawing up the proteins in solution into the
tubes. Here, the solution is incubated inside the tube for a period of time, to allow
for the protein to bind to the glass surface due to a difference in electric charge.
Once the surface is completely coated with a homogenous layer of protein, the
solution is removed from the tube, and the tube is washed with a PBS buffer for 5
minutes at 1000 s-1 shear rate to remove any loosely bound protein or debris.
Before finalizing this process, it was necessary to determine that our incubation
time would allow the protein solution to complete the coating process, whether the
resulting coat was a homogenous single layer of protein, and whether the post
incubation wash damaged the layer in any way. Also, the ability to remove protein
from the test tube surface needed to be investigated as future design iterations
would involve the reuse of a number of components, especially the test blocks.
4.1.2 VALIDATION OF THE COLLAGEN COATING PROCESS
4.1.2.1 QUALITATIVE VALIDATION OF COLLAGEN COATING
HOMOGENEITY
The first step in validating the collagen coating process investigated the
amount of incubation time necessary to lay a homogenous layer of collagen on the
interior of the test tubes. To determine this, a bovine Achilles tendon collagen II
solution was drawn up into test tubes and incubated for either 2, 4, or 20 hours, and
then washed out with PBS at 1000 s-1 for 5 minutes. The tubes were then immuno-
labeled with a a-bovine collagen II primary antibody and a rabbit a-goat FITC
secondary, and imaged with fluorescence microscopy at several points down its
length (Figure 27).
Chapter 4 61
Section of Test Tube
Proximal Mid Distal
0
E
0
4-
20
Figure 27: Results of varying incubation time of collagen coating process. 10x
magnification. 0 hours of incubation indicates the negative control which is a blank
tube with no collagen coating.
The results of varying the collagen solution incubation time qualitatively
indicate that a homogenous coat of collagen is laid down the length of the tube. An
increase in collagen content, or the thickness of the collagen layer is noted as the
incubation time increases, especially after 20 hours. This effect was likely caused by
drying out the solution over the period of incubation. This drying would cause
excessive deposition and layering of the collagen inside the tube, providing a thick
protein layer that may block the lumen of the tube. Therefore, the test would have to
be run again without allowing the solution in the tubes to dry out.
The test was repeated with precautions taken to avoid evaporation of the
solution. Two potential solutions were explored: plugging up the tube ends, and
submerging the tubes. Half of the tubes had their open end plugged up with a putty
after drawing up the collagen solution. Plugging up the end with putty prevented the
escape of the collagen solution from the tube lumen during incubation. The other
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half of the tubes were completely submerged in the collagen solution inside a
beaker, which would ensure that there would always be solution inside the tube and
that it would not dry out. The incubation times, wash process, and immuno-labeling
and imaging were repeated (Figure 28).
Incubation Time [hrs]
2 4 20 40
Plugged End
Submerged
Figure 28: Results of repeating incubation time experiment with the addition of 
end
plugging and tube submerging to avoid solution evaporation.
The results of this new incubation time test reveal that solution evaporation
was indeed the reason for the thick collagen layers after long incubation times. At 2
hours and beyond the collagen layers are qualitatively equal in density. It was also
found that the tubes with their ends plugged up with putty resulted in much more
homogenous distributions of collagen coating compared to the tubes that were
submerged in collagen solution. This may be due to air bubbles becoming entrapped
in the tubes after submerging. This test qualitatively revealed that the collagen
coating process is saturated by 2 hours of incubation time. To ensure that increasing
the incubation did not result in a thickened collagen layer, a quantitative test would
be required.
4.1.2.2 QUANTITATIVE VALIDATION OF COLLAGEN COATING
HOMOGENEITY
The final test in ensuring that a saturation point was reached during the
collagen incubation process was a quantitative measure of the amount of collagen
coating the tube. A procedure involving the picro-Sirius red staining of the collagen
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coat, followed by a colorimetric assay was adopted [56]. For the test, test tube
segments were coated with collagen by drawing in the collagen solution, then
plugging up the end and incubating for 2, 10, or 24 hours. The tubes were washed
with PBS, then the collagen was fixed, incubated with picro-Sirius red dye,
hydrolyzed with NaOH, and expelled into the wells of a 384-well plate. The wells
were read by a spectrophotometer at a wavelength setting of 650 nm, (Figure 29).
Sirius red assay of collagen coating
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Figure 29: Results of the absorbance measurements of Sirius red staining of the
collagen content of tubes incubated for different amounts of time (n=3). 0 incubation
time represents the negative control which is tubes that were not coated with
collagen. (* = p<0.1 and ** = p<0.05, with respect to negative control data.)
The results of this test show that the 2 hour incubated test samples provided
a 25% increase in absorbance. On the other hand, after 2 hours of incubation, little
to no difference is noted in the absorbance, and therefore, the amount of collagen
contained in the tubes. In addition, the standard error in the data for each
incubation time group is on the same order as the standard error for the negative
control group, further indicating little variation from the collagen coating saturation
point. Therefore, two hours of incubation with collagen solution will suffice to reach
a collagen coat saturation point.
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4.1.2.3 VERIFICATION OF CELL ADHESION TO COLLAGEN COAT &
TUBE CLEANING
After determining that the test tube collagen coat was homogenous, it was
necessary to verify the nature of cell binding to the collagen. The main questions to
be answered involved whether the binding of blood components to the collagen was
homogenous and determining whether the buffer flush step was too aggressive and
would wash away portions of the thrombotic signal bound to the tube. In addition, it
was important to determine whether blood components and collagen may be
removed by a cleaning process so that tubes may be reused in the future.
Freshly drawn and untreated blood was run through collagen coated tubes
for 2 minutes at a 1000 s-1 shear rate to allow for the buildup of thrombotic burden.
The tubes were then flushed with Tyrodes buffer in the normal manner, a lysing
solution was applied, and an a-actin FITC immuno-label was applied to the tube
lumens. The tubes were then imaged through fluorescence microscopy. The actin
contained in the cells bound to the collagen would tag the cell remnants left bound
to the collagen in the tube, and provide a good indication of the density of cells
bound to the tube wall. The results of actin immuno-labeling compared against a
negative control are shown in Figure 30.
Tube Location
Proximal Distal
Blood Exposed
No blood exposure
(negative control)
Figure 30: Results of actin immuno-labeling. Blood exposed images performed at 5x
magnification, no blood exposure images performed at 10x magnification.
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The results show a qualitatively homogenous distribution of immuno-labeled
actin across the length of the test tube. In addition, since the application of the
antibody was performed after the Tyrodes buffer wash was performed, the images
also show that the bound cell components were resilient against the stress placed
on them from the wash.
To further investigate the strength of the bound blood components, we
considered the effect of cleaning the tubes with a variety of harsh conditions. The
goal of these tests is to potentially allow for the reuse of the test block components
of the flow model. As testing with this system continues to evolve, the need for test
blocks (costly in both manual labor time and materials) will only grow unless a
method of reusing the blocks is developed. Cleaning strategies that are capable of
removing bound cell components as well as cleaving and/or hydrolyzing the
collagen coating were investigated.
A variety of aggressive cleaning agents, such as collagenase, urea, and HCl,
were first employed to remove the collagen coating. This test utilized tubes coated
with collagen incubated for 2 hours. After the normal buffer wash procedure,
collagenase (1mg/mL solution), 2M urea, or 6.5M HCl solution was drawn up into
the tubes and incubated at 370C for 60 minutes. The cleaning agent was then
removed and the tubes were washed out with a 2% Sodium Dodecyl Sulfate (SDS)
solution followed by deionized water at 1000 s1 for 5 minutes. The tubes were then
immuno-labeled with a-goat collagen II antibody and a FITC a-mouse secondary and
imaged with a fluorescence microscope (Figure 31).
Control Collagenase Urea HCI
Figure 31: Results of collagen removal testing. Images were taken at 10x
magnification. Each of the tubes were coated with collagen for 2 hours. Collagenase,
urea, and HCI were then drawn into the tubes and incubated for 60 minutes followed
by an 2% SDS and DI-H 20 wash. Qualitative results show that HCL provided the most
effective collagen removal.
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The results of the collagen removal testing indicate that incubation of 6.5M
HCL in the tube provided better cleaning results than incubation with collagenase or
urea. The results with HCL were not perfect, and the results are also not capable of
determining whether the incubation with HCL actually caused the collagen to
deform, as opposed to simply hydrolyzing and hindering the antibody's ability to
bind to the protein, giving us a false negative result. To further investigate this
cleaning process newly collagen coated tubes were exposed to blood and the HCL
incubation process was repeated.
In this follow-up test, collagen coated tubes exposed to a 1000 s-1 blood flow
for 2 minutes were immuno-labeled with an a-actin FITC antibody, and incubated
with 6.5M HCl, followed up by a wash with 2% SDS, then a wash with an aggressive
cleaning buffer formulated to remove cell components and hydrolyze bound
collagen (100mM tris base, 3% SDS, 2% Triton-X, 2M NaCl, 6M Guanidine HCl).
Finally, the tubes were immuno-labeled once more. The image results pre and post
the second labeling are shown in Figure 32.
Blood Exposed Washed once Washed again (using Re-labeled
(using HCL & 2% SDS HCL & improved
solution) cleaning buffer)
Figure 32: Results of repeating HCl incubation cleaning and staining for actin bound
to collagen coat. Images were all taken at 5x magnification, except for "Re-labeled"
image which was taken at 10x magnification.
The results of the HCl cleaning of tubes indicate that the 6.5M solution of HCl
removes a large part of the bound cell components, but use of the improved cleaning
buffer provides much more encouraging results than washing solely with the 2%
SDS solution. Re-labeling the bound actin may have brought out slightly more
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previously unmarked actin strands, but the actin content of the tube is significantly
less than that of the blood exposed tubes.
This testing will have to be developed further to ensure substantial removal
of all cellular debris and collagen such that it will not interfere with the
reapplication of collagen and the reuse of the tubes in the flow model. Perhaps slight
modification of the HCl incubation or buffer washing procedures will provide the
desired results. The only way to finalize the efficacy of the washing process will be
through repeated blood testing on the 384- or 24-channel flow model, to monitor
for the possibility of cell remnants disturbing the results of subsequent tests. Final
validation of the tube cleaning process will greatly increase the cost effectiveness of
the device by decreasing many of the variable costs of testing such as the manual
labor and the materials used to manufacture the test blocks.
4.1.3 12 CHANNEL FLOW MODEL
The preliminary biological characterization of the flow model of thrombosis
was performed on a bench top prototype of the multichannel system (Figure 33).
The system featured 6 to 12 individual flow channels of identical inner diameter to
those used in the 384-channel and 24-channel concepts. The flow through the
channels was actuated by means of a syringe pump properly set to achieve the
desired flow rate in all the channels, connected in a parallel fashion.
Figure 33: Initial 6 to 12 channel flow system powered by syringe pump.
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This set up is capable of testing a single shear rate at a time, through a set of 6 to 12
glass tubes of equal dimensions, each with interior wall coating as prescribed. The
blood supplied to the system came from a single source; therefore a single blood
treatment condition could be tested at a time. An important limitation to note about
this machine was its use of volumetric flow rate control as opposed to pressure
control. Therefore, an assumption is made that the current through each branch of
the circuit will remain the same during the test. In reality, the flow in each branch of
a current controlled system is highly subject to changes in the currents in every
other flow branch. So if any single branch experienced reduced flow rates due to a
blockage, all the other branches would experience a commensurate increase in
blood flow given that the blood now has fewer branches through which to travel. As
a result, during the testing process, it was vital to note if any tubes became blocked
off, so that they may be cleared or so the resulting shear rate in all of the other tubes
could be calculated.
This model would allow for a number of preliminary tests to validate the
efficacy of the assay system in combination with the test tubes used in the final 384-
channel flow model. Primarily, this model would test with tubes identical to those of
the final model, utilizing flow shear rates and blood run times similar to those
intended for the full-scale machine, and the identical test process would be used on
this system. The testing goals comprised resolving differences in thrombotic
outcomes between test subjects, differing shear rates, blood treatments, and
ensuring sufficient precision between tests with identical input parameters.
4.1.3.1 METHODS AND RESULTS
DETERMINING MINIMUM SAMPLE SIZE
The first biological validation system testing involved determining the
minimum sample size necessary to provide reliable results through precision. In
addition, we investigated the effect of varying blood condition. Two test samples
from the same blood draw, one treated with 1.5ptL/mL PPACK (an anti-platelet
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drug), the other treated with 8.0piL/mL PPACK were run through the tubes for 2
minutes at a shear rate of 1000 s-1. The tubes were then washed with Tyrodes buffer
for 5 minutes at a shear rate of 1000 s-1, and assayed for thrombosis products
(Figure 34).
Varying amount of PPACK
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Figure 34: Results of varying PPACK levels show increased thrombotic activity at
higher blood PPACK levels (n=3). The purpose of the test was to determine minimum
number of test repeats necessary to ensure reliable results. An n = 3 proved to have
low error. (*= p<0.05, with respect to 1.5pL PPACK data.)
The results of this test provided unexpected results in that the blood sample with a
greater amount of PPACK provided a higher signal than the sample with less drug
added. The results were speculated to have been due to the relatively greater role of
platelet activity (as opposed to coagulation) in thrombogenesis at higher shear
rates. The 1.5tL and 8.0ptL PPACK tests both had n = 3, and resulted in a standard
error of 1.3% and 2.9%, respectively. Although unexpected, the results of this test
indicate that using 3 repeats of each condition would be sufficient to provide
reliable results during validation testing.
EFFECT OF RUN DURATION ON SIGNAL
The next test re-examined the anti-coagulant blood treatment, while varying
the blood run duration. A single blood draw was split into two groups and treated in
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the same manner as the previous test (1.5ptL or 8.0ptL PPACK). In addition, the 2
blood treatment groups were further split into two groups: the first where the blood
was run through the tubes for 1 minute, while the other group allowed blood to run
for 2 minutes. All blood samples were run at a 1000 s-1 shear rate through collagen
coated tubes, washed for 5 minutes at 1000s1, and assayed normally (Figure 35).
Effect of blood run duration on signal
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Figure 35: Results of varying test run duration (n=1 for 1 minute, 1.5PL PPACK data;
n=4 for all other data groups). Longer run times provided higher signals in the 2
minute data, as expected. Unexpectedly, increased levels of PPACK in the blood
increased the thrombotic activity in the 2 minute run data. (*= p<0.05, with respect
to 2 minute, 1.5piL PPACK data.)
Once again, the results showed higher levels of thrombotic activity in the
8ptL/mL PPACK exposed samples, but only in the 2 minute run data. Unfortunately a
test problem provided an n=1 for the 1 minute, 1.5 ptL/mL PPACK data group. On the
other hand, the results of varying the test run duration indicate, as expected, that a
longer run time produced a greater amount of thrombotic burden in the tubes.
Doubling the run time in the 1.5ptL and 8.0ptL PPACK groups provided a 27% and
50% increase in thrombotic signal, respectively. The results of this test indicate the
strong dependence between run time and signal, which will prove useful in order to
calibrate the thrombotic fingerprint to best resolve detail.
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EFFECT OF SHEAR RATE ON SIGNAL
The flow condition axis of Virchow's Triad was next to be investigated. A
single draw of blood was treated with 6ptL/mL of PPACK and was run for 2 minutes
at 100s-1 or 1000s-1 shear rate through collagen coated tubes. The tubes were then
washed out with buffer for 5 minutes at 10OOs-1 and assayed. The same test was run
again the next day, using fresh blood from the same volunteer, in order to
investigate the variation in results on a day to day basis (Figure 36).
Effect of blood run duration on signal
0.012
0.01 -
E
0.008 -
.2
0.006 -
50.0024
0L
1.5uL/mL PPACK SuL/mL PPACK
M I minute M 2 minutes
Figure 36: Results of varying blood shear rates and repeating the same test the next
day (n=6 for Day 1 data sets, n=4 for Day 2 data sets). (*= p<0.05, with respect to Day
1, 100 s-1 data; ** = p<0.0 5, with respect to Day 2, 100 s- 1 data.)
The increase in thrombotic signal came as an expected result of the increased
shear rate causing the heightened levels of platelet excitation and activation. This
result confirms the relevancy of our process' outcomes by matching the results of
shear rate variation that have been acquired from previous models. In addition, the
results of the tests show the amount of day to day variation innate to the blood and
the thrombotic components and processes within it. The results of this test indicate
that legitimate comparisons between test results could only be made from blood
samples derived from a single draw and tested concurrently. Therefore, this will
have to become the standard of our testing and data acquisition processes. This
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further supports the need for the embodiment of our concept to test a large number
of samples in parallel without requiring prohibitively large blood samples, to form
relevant comparisons and resulting deductions from our data.
EFFECT OF VARYING BOTH SHEAR RATE BLOOD CONDITION ON SIGNAL
Due to the interesting results derived from adding PPACK to blood samples
and comparing against untreated samples, more tests were performed to determine
the nature of the interaction between the PPACK treatment and the shear rate. The
tests involved addition of 8p.L/mL of PPACK to a blood sample and comparing
against a negative control of untreated blood from the same draw. The samples
were tested at 1000 s-1 for 2 minutes, and were washed at 1000 s-1 for 5 minutes.
Another test was performed with blood from the same volunteer, and treated in the
same manner except that the flow conditions were set at 50 s-1. The results are
shown in Figure 37.
Varying Blood PPACK Levels & Shear Rate
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Figure 37: Results of varying blood PPACK content along with shear rate (n=3).
The results of these tests show a reduction in thrombotic signal as the PPACK
is added to the blood sample. Therefore, another blood sample, treated in the same
manner, was run at 50 s-1 to examine the shear dependent effects of the drug on the
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blood (Figure 37). Thrombotic activity decreased due to the decrease in shear rate: -
75% for the no PPACK group and -52% for the 8pL/mL PPACK group. This result
confirms the positive shear dependent result from the previous test. In addition, the
PPACK treatment caused a -62% and -28% change in signal for the 1000 s-1 and 50
s-1 groups, respectively. PPACK seems to have a greater effect in the higher shear
rates, which happens to be the realm where platelet activation plays a greater part
in thrombosis. In the lower shear realms, the coagulation cascade plays a bigger role
in the process; therefore a drug that affects platelet activity will have less effect in
these flow conditions.
4.1.3.2 12 CHANNEL TESTING SUMMARY
These preliminary validation tests run on the 12-channel device helped to
finalize the run, wash, and assay portions of the test protocol. The conditions run
during the tests provided evidence that our flow model and test procedure provided
sufficient parametric control and assay resolution over the process of thrombosis in
order to continue with the mechanical characterization of the higher-throughput
model concepts.
4.2 MECHANICAL CHARACTERIZATION OF THE FLOW SYSTEM
The mechanical characterization of the flow model involved three goals:
mathematical determination of the fluid flow and shear rate through an individual
channel at a variety of applied vacuum pressures, determination of the effect of the
collagen wall coating on flow characteristics, and mechanical characterization of the
24-channel flow model.
Chapter 4 74
4.2.1 VACUUM PRESSURE VS. FLUID SHEAR RATE
4.2.1.1 FLUID THEORY VS. EXPERIMENTAL RESULTS
The first aim sought to establish the mathematical relationship between the
vacuum pressure applied to the system and the shear rate experienced in the tubes.
Initial tests were performed on a single test tube of dimensions equal to those of the
test tubes utilized in the flow model (10 cm length, 0.3 mm ID, 1.27 mm OD). A
specific and constant negative vacuum pressure was applied to one end, while the
other was open to fluid. The resulting volumetric fluid flow was combined with the
pressure differential reading to back calculate the fluid shear rate at the tube wall
using the following equation:
61 32-Q
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Eq. 12
The test compared water against a 2:3 by volume solution of water and glycerol
which replicates the viscosity of blood at the shear rates we intend to test, which is
about 3-4 times the viscosity of water. In addition, the results (Figure 38) are
compared against the fluid mechanical theoretical data.
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Single Test Tube: Water vs. Water + Glycerol
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Data Set Slope [s/MPa] Error from Theory R2
Water (Theory) 748.* - -
Water 834.3 11.5% 0.972
Water / Glycerol (Theory) 249.4 - -
Water / Glycerol 144.8 - 41% 0.941
Figure 38: Test results for single test tube flow characterization. The test results for
water and the water/glycerol solution are compared against theoretical data for the
respective conditions.
The results of this first flow test provided evidence that our experimental
calculations of flow resistance (slope of trend line) are off by 11.5% and -41% for
the water and water + glycerol theoretical data sets, respectively. It is interesting to
note that the water provided less error and provided a higher slope than theory,
while the water + glycerol solution provided a slope lower than theory. Fortunately,
the strong linear grouping of the data suggests a high level of repeatability and
predictability in the flow system. The vertical displacement between the
experimental and theoretical data sets is due to systemic pressure losses from
imperfect seals, and must simply be compensated for by using the linear regression
of the experimental data as opposed to the theoretical formula.
Once the flow characteristics of a single test tube was established, the
combination of a single test tube and a resistance tube could be tested. The tests run
on the single test tube flow were repeated on combinations of the test tube with
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resistance tubes varying in inner diameter. A negative vacuum pressure was applied
to one end of the tubing and the other end was exposed to a container with either
water (Figure 39) or the 2:3 mixture of glycerol and water (Figure 40). The applied
pressure and resulting volumetric flow rate were recorded and used to calculate the
shear rate experienced by the inner wall of the test tube.
Pressure vs Shear Rate: Test + Resistance Tubes, Water
6000
5000
4000
3000
2000
1000
A
0
0 1 2 3 4 5 6 7 8
Gauge Pressure [inches Hg]
300 pm
188 gm (theory)
188 prm
151pgm(theory)
151 rm
101 gm (theory)
101 PM
+ 300um
300umtheory
* 188um
- 188 umrtheory
A 151um
151 umtheory
101 uM
101 umtheory
336.4 64.24% 0.965
211.2 - -
127.6 39.58% 0.982
92.4 - -
69.13 25.18% 0.891
19.04 - -
18.45 3.10% 0.964
Figure 39: Results of pressure vs. shear rate testing with the use of the test and
resistance tubing. The theoretical and experimental results for resistance tubing of
each ID are shown. (Trend lines for experimental data are not shown for purposes of
image clarity.)
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Pressure vs. Shear Rate: Test + Resistance Tubes, Water/Glycerol
Solution
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Figure 40: Results of pressure vs. shear rate testing with the use of the test and
resistance tubing in combination with the 3:2 water/glycerol solution to simulate
the viscosity of blood. The theoretical and experimental results for resistance tubing
of each ID are shown. (Linear trend lines are not shown for purposes of image
clarity.)
The R2 values of the linear trend lines on flow test results (Figure 39 and
Figure 40) indicate a strongly linear correlation between the applied vacuum gauge
pressure and the resulting test tube shear rate. The vertical shift between the
experimental and theoretical results is due to losses of pressure throughout the flow
system, such as imperfect seals between components, which are not accounted for
in the mathematics of the theory. The slopes of the theoretical and experimental
data encounter a significant amount of error when compared; indicating that the
theory does not completely encompass the flow resistances encountered in the flow
channels. Potential sources of this resistance calculation error may be the coupling
devices used to link together the test and resistance sections of tubing. Fortunately,
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the output parameters of this flow system, as observed through the R2 value, are
highly predictable, therefore flow conditions would be easy to control during blood
testing. Since the tubes that were tested were bare-walled, and the thickness of the
collagen coat was unknown, the effect of the collagen coat on the flow had to be
determined.
4.2.1.2 EFFECT OF COLLAGEN COAT ON FLUID FLOW
The next step involved determining whether coating the interior wall of the
test tube with a protein such as collagen builds up a layer thick enough to affect the
fluid flow. The protocol of the previous single-tube test was repeated with two
collagen coated test tubes (Figure 41).
Single Test Tube: Bare Wall vs. Collagen Coated
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Figure 41: Results of bare wall vs. collagen coated test tube flow testing.
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The results indicate a very small difference in the slopes of the bare-walled
vs. collagen-coated data series, reaching a maximum of a -10.8% difference in
measured shear rate of water at a 4 MPa pressure. This slope shift in the data should
prove to have little effect on the results of blood tests, as is evident in the
water/glycerol results, where there is only a -2% difference in slopes. Therefore,
collagen coating the tubes does not provide a large difference in the inner diameter
of the test tubes, and the flow effects remain negligible. The high R2 values indicate a
strongly linear data set, and therefore output flow parameters are highly
predictable.
4.2.2 24 CHANNEL FLOW CHARACTERIZATION
The final flow characterization test was performed on the 24-channel flow
setup without the resistance block attachment. A block with 24 bare walled tubes
was compared against a block with 24 collagen coated tubes. The volumetric flow
rate of both water (Figure 42) and the water/glycerol solution (Figure 43) was
measured while maintaining a constant pressure head.
24 channel block: Bare vs. Collagen Coated (Water)
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Figure 42: Results of flow testing on the 24-channel block running water throughbare-walled and collagen-coated wall tubing.
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24 channel block: Bare vs. Collagen Coated (Water/Glycerol)
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Figure 43: Results of flow testing on the 24-channel block running the
water/glycerol solution through bare-walled and collagen-coated tubing.
The 24-channel flow test results indicate a very predictable flow system
based on the very tight linear data trends as observed by the R2 values. Little
difference is noted between the results for the bare-walled and collagen-coated
tubes. Specifically, the error from theory in the slopes of the trend lines of the
collagen coated tubes for the water/glycerol results were 8.14% and 3%,
respectively, which cause little deviation in results over the range of pressures at
which we test. The data suggests that collagen coating actually gives results closer to
theory, and furthermore, that the addition of glycerol to the water brought the
experimental results even closer to theory. On the other hand, it is also important to
note that the vertical shift between the theoretical and experimental data is greater
in these tests as compared to the single channel tests. This is due to the increased
losses in the system pressure head due to imperfect mating between the test block
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and vacuum connection, and between the test block and blood loader components.
Finally, the resulting equations from the linear regression:
y = 522.4x - 651.7 Eq. 13
y = 119.8x - 190.4 Eq. 14
can be used to determine the vacuum setting necessary to achieve the desired flow
shear rates through a 24-channel test block.
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CHAPTER 5: DEVICE APPLICATION - DEVELOPMENT
OF THE THROMBOTIC FINGERPRINT
Once the initial development and conceptual validation of the device was
completed, it was possible to move on to the application of the device by means of
the 24-channel system, to begin elucidation of the thrombotic fingerprint. The
development of the thrombotic fingerprint began with optimization of the testing
and assaying procedures to reduce noise and improve repeatability of the results.
Next, the 24 channel system was utilized to begin testing for baseline fingerprint
characteristics that will form the foundation of fully developed and detailed
thrombotic fingerprints. Finally, the plans for future investigations to extend the
reach and depth of the thrombotic fingerprint were laid out.
5.1 PROCEDURE OPTIMIZATION
5.1.1 DAY TO DAY VARIATION
The thrombotic propensity of an individual's blood is dependent on the
integration of a large number of factors, some of which may vary on a daily, or even
shorter, basis. These factors may be environmental, nutritional, or even
psychological in nature. Due to this uncertainty, it was determined that preliminary
applications of the flow model would require comparisons on results to be
performed on a single day's blood samples. In addition, result variation may be
simply due to the manner in which the blood was drawn and handled thereafter,
necessitating comparisons to be made only between the test results derived from a
single sample draw. This precaution would instill a much greater confidence in our
preliminary results, as we are trying to form a basic understanding of the
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parametric dependence of the thrombotic fingerprint. It is expected that as testing
progresses, it will be possible to compare blood samples taken at different times as
the thrombotic fingerprint will be better developed and the limits to an individual's
variation will be understood.
5.1.2 MACHINE AND PROCESS NOISE
The processing of the test samples encounters a number of variable steps
that may add or reduce the noise encountered in the results. These steps include the
rate and extent of the Tyrodes buffer washing step, the use of a 5% Triton-X solution
as a cell lysing agent, as well as the manner in which the colorimetric assay is
applied and measured.
5.1.2.1 BUFFER WASHING
The buffer washing step immediately follows the blood test run, and involves
passing a saline buffer through the channels of the flow system at a uniform shear
rate. Initial tests utilized PBS as the buffer, but it was soon found that this solution
was too harsh on the bound thrombotic products contained in the tube. The solution
was then changed to a Tyrodes buffer with added MgCl (0.75 mMol) and HEPES (10
mMol), which helps protect the ionic environment needed by the platelets to remain
strongly bound to the channel wall. The thrombotic signal from testing with Tyrodes
was a stronger and more consistent thrombotic signal. The other variables involved
with the wash step include the flow shear rate and the wash time length. The initial
parameters chosen were a buffer wash of 5 minutes at a shear rate of 1000 s-1,
derived from the protocol created by Kolandaivelu [18]. After performing the cell
debris and collagen removal testing explained in Chapter 4, it was qualitatively
determined that the bound thrombotic components were resilient against a wide
range of shear rates and wash times. Therefore, we believe that the wash
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parameters chosen are sufficient to uniformly remove loosely bound blood
components while not upsetting the true thrombotic signal.
Finally, depending on the flow rate, wall, and blood conditions of a test, blood
in some channels would completely clot and prevent further flow through it. During
the wash phase it would be possible to break off the clot and reopen the channel to a
flow. If the clot remained, it would be blown out in a subsequent step, when a high
pressure air flow was passed through the channels to remove any remaining fluid to
allow for the assaying of the results. Initially, the hope was to remove the loosely
bound clot and maintain the components more strongly bound to the channel wall.
Results soon showed a great deal of result variation from the clotted channels,
indicating that blowing out the clot with buffer or air produced an all or nothing
effect on the thrombotic signal. Specifically, the signal would be polarized: it would
either be higher than all other channel signals, or the signal strength would be on
the same order as the negative control. The conclusion derived from these
observations was that channels that became clotted over the period of a test would
have to be discounted, as their results did not provide significant insight into the
thrombotic fingerprint.
5.1.2.2 CELL LYSING
According to the original protocol by Kolandaivelu [18], from which we
based our protocol, a 5% solution of Triton-X was used to lyse the cells bound onto
the model's reactive surface, to release LDH into the surrounding medium and
perform the assay. As Triton-X is a surfactant, it may permeate cellular membranes
and burst the cell, it also has a soapy nature which readily forms bubbles following a
process that may agitate and introduce air into the solution. During the lysing step
of the assay process, the Triton-X solution is drawn up into the channels from
individual wells on a 384-well plate. After a period of incubation (normally 30
minutes), the solution with all contained cellular elements is expelled back into the
well. This step proved to be problematic during initial testing, as bubbles would
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readily form at the channel tip feeding into the well plate and the expelled solution
frequently overflowed from the wells, mixing with the surrounding expelled
solution. De-ionized water was proposed as a lysing agent to replace the Triton-X
solution. A serial dilution of blood in Tyrodes buffer was performed on a 96-well
plate, then the samples were lysed with 5% Triton-X solution or de-ionized water,
and an LDH color assay solution was added (Figure 44).
Blood Dilution: Triton-X vs. DI Water Lysing Solutions
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Figure 44: Results of lysing a variety of blood dilutions with
(T-X) and de-ionized water (DI) plotted in a semi-log manner.
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There is little to no difference in the LDH signal from the samples lysed with
Triton-X and those lysed with de-ionized water. Both the Triton-X and de-ionized
water treated samples provided absorbances higher than the samples with no
added lysing agent. A reason for the relatively high values of the samples with no
lysing agent is the fact that whole blood was diluted for this test as opposed to solely
platelets. The whole blood adds a red color to the solution, even before addition of
the LDH substrate, due to the red blood cells and the iron of the hemoglobin. The
results indicate that Triton-X and DI water are equally good as lysing agents. The
benefit of the de-ionized water is its ability to be drawn into the channels and
expelled back into the wells without forming bubbles that may mix with the samples
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in other wells. For these reasons, de-ionized water was finally chosen as the lysing
agent for the subsequent experiments performed on the 24-channel system.
5.1.2.3 COLORIMETRIC ASSAY
The final step to retrieve the test results involves adding a cytotoxicity assay
(LDH substrate) solution to the samples. The assay changes the color of the sample
to different intensities of the color red, which is then analyzed for light absorbance
at 490 nm wavelength in a spectrophotometer. Optimization of this step involved
three aims: determining the effect of dye on the absorbance reading, determining
the effect of LDH substrate incubation time on the results, and correlating sample
absorbance readings to measurements of LDH content in a sample.
Performing the lysing step during assay proved to be a challenge due to the
clarity of the lysing solution in the thin tubes making the process very difficult to
visualize. To ease the difficulty of this step, India Ink was added to the lysing
solution (de-ionized water) to improve the visibility of the solution when drawing it
up into the channels. During this step it is very important to ensure that none of the
lysing solution overfills the channels and flows out through the top, as this would
cause you to lose some of the signal contained in the solution of that channel. The
increased visibility of the fluid allowed the user to maintain the lysing solution
drawn up at a safe level. Since the India Ink is of a purple/blue color, it was
hypothesized that it would have little effect on the spectrophotometer reading, since
it was performed at the 490 nm wavelength absorbance setting, specific to the red
color generated by the LDH substrate. To test the effect of the ink, a serial dilution of
blood in Tyrodes buffer was lysed with either dyed or un-dyed lysing solution, and
then the LDH substrate was added. In addition to the effect of dye, the test also
investigated the effect of LDH substrate incubation time on the strength of the
absorbance signal (Figure 45).
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Figure 45: Plotted results of effect of dye on serial dilution of blood. Samples had no
dye added to them unless stated. (Top) All results plotted. (Bottom) Magnified view
of the data points in the dashed sqaure in the top plot (up to 0.01 concentration of
blood).
The vertical shift in absorbance due to the dye added to the lysing solution is
not simply constant, but rather, decreases as the blood concentration increases. This
result indicated that the ink was not pure enough in color to use for this test and
either another ink that wouldn't interfere with the absorbance reading would have
to be used, or the lysing solution would have to remain clear and more care would
have to be taken when drawing up the solution. A substitute ink has not yet been
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employed, so more care has been taken to draw up the fluid, which has proven to
work satisfactorily.
In addition, the plot also indicates very little difference in the results of
incubating the samples with the LDH substrate for a variety of time. This allows for
a more loose control over the time spent in this step, although it is always favorable
to keep a record of the incubation time, and to try to keep it constant across all tests.
Finally, the dilution experiment indicated that we were only beginning to enter the
sensitive region of the LDH substrate, as the majority of our results remained on a
relatively flat region (about 0.1 absorbance reading), while the 100% blood sample
provided a much higher signal (about 4.0 absorbance reading). The sensitive region
of the assay should fall between these two points, as should the results of our blood
testing; therefore a dilution of LDH with greater resolution would be needed.
In order to covert the absorbance result into a measurement of the LDH content of a
sample, an LDH calibration curve was created by performing a serial dilution of LDH
in Tyrodes buffer, adding the LDH substrate, and reading the 490 nm wavelength
absorbance result on a spectrophotometer (Figure 46).
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Figure 46: LDH standard calibration curve plotted on semi-log axes. The area
between the two vertical lines depicts the cytotoxicity kit's region of sensitivity. This
region is characterized by an absorbance reading that is linearly proportional to the
LDH concentration of a sample. The inset plot shows the linear regression and
equation used to convert between absorbance readings and LDH concentrations.
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Note that these results were read on a different spectrophotometer than the one
used to acquire the results shown in Figure 45. Therefore the absorbance
measurement scales may not match up.
The results of the LDH dilution indicate a region of absorbance linearity
between LDH concentrations of 0.2% and 1.0%. Outside of this region, the assay kit
cannot be considered linear, and therefore results outside the region of sensitivity
cannot be compared to results inside the region.
At this point, preliminary application testing on the 24-channel device could
commence testing parametric variation to establish the rough characteristics of the
thrombotic fingerprint.
5.2 CHARACTERIZATION OF THE THROMBOTIC FINGERPRINT
The validation testing afforded us the necessary confidence in our system
and procedure to enter the early stages of blood testing with the use of the 24-
channel device. In a manner very similar to that employed during the initial 12-
channel biological validation, a set of preliminary tests for the 24-channel device
were devised. The first set of tests performed on the 24-channel system were
planned to establish the thrombotic fingerprint foundation, or baseline results, by
exploring its inherent precision, signal variation from one test to another, and finally
the effect of manipulating the testing parameters on the thrombotic signal.
5.2.1 SYSTEM PRECISION
The first blood tests were performed on a single test block with 12 or 24
collagen-coated channels. Fresh, untreated blood was drawn from a volunteer and
run through the channels of the test block at a shear rate of 1000 s-1 for 2 minutes.
The runs were followed by a Tyrodes buffer wash at 1000s-1 for 5 minutes, and
assaying of the results. These tests allowed us to investigate the variation inherent
to blood, the system, and the pre- and post-blood run process steps. Analysis of this
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type allowed the testing process to be tweaked to provide a tighter, more reliable,
set of results over time. Once the system variability was brought to a level low
enough to ensure clarity of results, baseline blood tests were performed.
5.2.1.1 INTRA-INDIVIDUAL VARIATION
The first goal of the baseline blood tests was to establish the amount of test
variation that may be expected from a single volunteer's blood test results from one
day to the next. Blood was collected from two individuals each day for two days, run
through the flow model at a shear rate of 1000 s-1 for 2 minutes, and washed and
assayed as normal (Figure 47 and Figure 48).
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Day 1
Figure 47: Average absorbance result of the consecutive day testing for the 2
individuals (data for individual 1 has n=9; data for individual 2 has n=14). (*=
p<0.05, with respect to Individual 1, Day 1 data)
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Figure 48: Histograms of the results from the consecutive day blood tests. The x-axes
on both histograms are the same so that the horizontal shift of data distributions can
be observed between the two individuals (data for individual 1 has n=9; data for
individual 2 has n=14).
The results from the consecutive days of blood tests indicate the highly
volatile thrombotic nature of blood. Provided that all testing conditions were
equivalent, the differing environmental, dietary, physiological, and psychological
conditions individuals encounter on a daily basis provided a -33% change in
thrombotic activity for individual #1, and a 22% increase for individual #2 after just
a single day of delay time between tests. The data spread shown in the histograms
(Figure 48) indicate that the two days' data sets cover fairly similar ranges, while
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distributing their point density differently in this spread. This result may be
explained by one of two reasons. Since the data spread from the second day for both
individuals seem to be equally spread out with no significant peaks, a protocol error
may have occurred on the tests of this day, injecting a great deal of variability in the
day's data. On the other hand, this data may provide evidence that the day to day
variation is occurring within a larger envelope of physiologic limits specific to the
individual.
5.2.1.2 INTER- INDIVIDUAL VARIATION
The consecutive day tests on the two individuals also provided data which
roughly showed the extent to which the current system can resolve between the
blood characteristics of two different individuals. A histogram showing the
difference in results between individuals #1 and #2 (Figure 49).
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Figure 49: Histogram of the day 1 blood test results of individuals #1 and #2.
The cross-individual results show a clear separation between the two
individuals' results distributions. As expected, each individual maintains a personal
fingerprint of their thrombotic capabilities, therefore the results (Figure 49) were
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encouraging in that our model was capable of clearly discerning basic differences
between individuals. The next steps would involve manipulation of a single variable
at a time to further influence the results and compare the outcome to some of the
well understood principles of platelet activity.
5.2.2 SINGLE PARAMETER VARIATION
Once an understanding of the natural distribution of the thrombotic signal as
well as the level of inter-test variability was established, the primary foundation of
the fingerprint could be continued to be laid through parametric manipulation. By
varying a single parameter at a time, we could acquire a general understanding of
our system's ability to illustrate the better understood concepts of the biology of
thrombosis.
5.2.2.1 FLOW CONDITION MODULATION: SHEAR RATE EFFECTS ON
THROMBOTIC SIGNAL
The first test featuring parametric manipulation involved comparing the
effects of low shear flow conditions to those resulting from relatively high flow
conditions. Untreated fresh blood from a single draw was aliquoted into two groups
and used during two consecutive flow tests. The two tests were run through
collagen coated tubes for 2 minutes at either a shear rate of 500 s-1 or 3200 s-1. The
tests were followed by a normal wash procedure (Tyrodes buffer + MgCl + HEPES
for 5 minutes at 1000 s-1) and assayed (Figure 50).
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Figure 50: Results of high vs. low shear rate testing. (Top) Average absorbance
measurement of data set compared against blank wells with no blood content.
(Bottom) Histogram of results to show the distribution of the data (the 500 s-1 data
has n = 8, and the 3200 s-1 data has n = 7).
The results of the high vs. low shear rate testing provided an unexpected
outcome in that the 500 s-1 shear rate actually provided a stronger thrombotic signal
than the 3200 s-1 shear rate group, even though the opposite result was expected.
The tight grouping of data for each flow condition, the clear group separation shown
in the histogram, combined with the number of samples for each test instills
confidence in these results as opposed to writing them off as random fluctuations
due to experimental noise. Note the extremely low signal of the 3200 s-1 test results,
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due to experimental noise. Note the extremely low signal of the 3200 s-1 test results,
which approaches the level of the negative control blanks that contain no products
of thrombosis. This brought us to postulate our first hypothesis about this
phenomena, which was that at this elevated shear rate, the thrombogenesis
occurring on the collagen coated walls of the tubing was simply not robust enough
to withstand the hydrodynamic forces of the high-shear-rate blood flow. Therefore,
much of the thrombotic burden may not have built up on itself, but rather was
washed away by the stream.
The second hypothesis put forth questioned the effect of the low shear rate
on thrombosis. At low shear rates, the coagulation cascade comprises the majority
of the blood's thrombotic effort as can be seen in deep vein thrombosis cases. On the
other hand, at high shear rates platelet activity takes over the clotting process. The
tests run at 500 s-1 may have emulated low flow, even stasis conditions, which may
have more strongly supported the coagulation reactions than the 3200 s-1 condition
may have supported platelet activity and binding. To study the low shear conditions,
the blood condition parameter had to be manipulated and tested.
5.2.2.2 BLOOD CONDITION MODULATION: EFFECT OF
ANTICOAGULANT ON THROMBOTIC SIGNAL
To investigate the hypothesis that the low-shear conditions brought about
the high signal due to high coagulation activity, the use of anticoagulant was
proposed. Treating a blood sample with an anticoagulant drug such as Heparin will
inhibit the coagulation cascade which is prevalent at low shear rates and during
stasis conditions. The resulting thrombotic signal will then mostly, if not completely,
be a result of the binding of activated platelets. Blood from a single draw from the
same volunteer that provided the sample for the high vs. low shear rate testing, was
broken into two groups. One group was treated with Heparin while the other
remained untreated. The two blood samples were then concurrently run though test
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block with collagen coated tubes at a 500 s-1 shear rate, followed by the normal
wash and assay steps (Figure 51).
Untreated vs. Hepariinized Blood
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Figure 51: Results of untreated vs. heparinized blood testing. (Top) Averageabsorbance readings from the untreated and heparinized groups. Results are alsocompared against samples negative control blanks, which contain no blood content,as well as empty wells, which contain no fluid. (Bottom) A histogram of the results toshow the distribution of results (untreated results have n = 3, and heparinizedresults have n = 5).
The results shown in Figure 51 indicate a very small signal difference
between the untreated and anticoagulated test groups, which are still higher than
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the negative control signal. The histogram reveals that the majority of the
heparinized signal resides among the untreated blood signal, essentially proving no
difference in thrombotic signal strength. These results led to two possible
conclusions: either the majority of thrombotic activity occurring at a 500 s-1 shear
rate is due to the activation and binding of platelets and not the coagulation cascade,
or some error in the test procedure caused a major loss of the signal. Due to the
extremely large difference between the untreated blood signals at 500 s-1 from the
high vs. low shear and untreated vs. treated blood tests (0.977 vs. 0.11), the result is
most likely due to a preparation error with the tube collagen coating step.
Therefore, the test will have to be repeated to provide more conclusive results.
The application of the flow model to the scenarios presented in the previous section
represents the very first observations obtained from parametric variation of the
thrombotic signal. The large amount of validation testing and resulting design
modification on the device has eventually brought us to a point where precision
optimization now allows us to place confidence in the blood test results. During this
period we are shifting from device development to device application, therefore
experimentation to characterize the thrombotic fingerprint is ongoing, and is
subject to an investigatory plan laid out in the following chapter. The upcoming
steps of the project will involve the parallel goals of characterization and
optimization of the thrombotic signal, as well as system optimization to reduce costs
and increase efficiency. These steps will help in reaching towards the future goal of
high-volume testing to build a library of thrombotic fingerprint information.
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CHAPTER 6: FUTURE DIRECTIONS
The immediate future of this device involves a focus shift from device
development to that of device application. The conceptual framework for the
creation of an individualized thrombotic fingerprint as well as a prototype of a
device capable of generating this thrombotic fingerprint, have been established. The
new goal is to now establish the collective set of run conditions that will define the
thrombotic fingerprint and to eventually experimentally validate this model. Three
milestones will have to be met to reach this new goal: manufacture of the high-
throughput system for application testing, optimization of the thrombotic
fingerprint, and establishing libraries of the thrombotic fingerprints.
6.1 MANUFACTURING HIGH-THROUGHPUT SYSTEMS FOR
APPLICATION TESTING
The application testing phase of this project has begun, and it has become
evident that first round testing may be performed on the 24-channel device, but
effective application testing of the device will eventually require a large number of
blood runs to be performed. This future direction necessitates the shift from the 24-
channel device to the full-sized 384-channel flow model. As explained in Chapter 3,
this device will incorporate a maximum of 16 test blocks with their associated
resistance block, as well as the supporting hardware such as the full-sized vacuum
connection and blood loader components. Specifically, the components necessary
for four stand-alone full-sized systems are planned for manufacture, as well as more
than 100 test blocks. This number of components will allow for streamline testing as
devices are set up, tested, and cleaned. Following full-scale model completion,
systemic troubleshooting will follow immediately with the understanding that many
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of the design problems have been revealed and resolved with the use of the 24-
channel device.
A secondary aim during the process of high-throughput model manufacture
is a further enhancement of component manufacturability and process automation,
while minimizing the operator effort during machine use. As the project moves
forward, an ever-increasing number of test blocks will be needed, which raises
concerns regarding the fixed versus variable costs items, as well as the cost of labor
to manufacture all the test blocks. Attention will be paid to the man hours involved
in the test block and resistance block mold setup, as well as the variable expense
costs of items such as the glass capillary tubes used in the test blocks, which may
become a limiting factor during testing. This variable cost will be tended to through
the limited-reuse of glass channels (after establishing a satisfactory cleansing and
sterilization formula), and through comparison shopping of the glass tubes such that
they may be bought in bulk, at wholesale pricing. In addition, new design
modification strategies to end the model's dependence on the glass tubing, are being
taken into account. One strategy currently being explored is to cast flow channels
directly into the silicone rubber of the test blocks, rather than use the implanted
glass tubing. This modification could significantly improve ease of set up and cost
during large scale production and testing. As a general rule, throughout all these
stages of testing, attention will continue to be paid to keeping the machine
compatible with future process changes, with the projected goal of full system
automation.
6.2 PARAMETER SPACE DEFINITION AND OPTIMIZATION
The definition of the parameter space inspired by Virchow's triad will
continue to be explored with use of both the 24-channel and 384-channel flow
models. This testing is to be performed with the use of citrated whole blood
obtained from the Red Cross and normal volunteers, and replenished with divalent
Chapter 6 101
cations (calcium and magnesium) in order to capture a broad region of thrombotic
information. After a sufficient amount of data has been collected, a critical part of
development of the thrombotic fingerprint will be determination of a set of run
conditions that define an appropriately large, while at the same time, appropriately
detailed parameter space. In the field of finite-element analysis, a well-recognized
problem is the designation of a geometric mesh that appropriately covers a
designated area, some parts of which may undergo large amounts of change in a
relatively small area, while other parts may remain relatively stationary. This
problem is solved by utilizing a optimal gridwork that has a fine mesh size in
regions of rapid change, while a mesh with larger, more widely spaced elements is
used in regions of gradual change. The optimization of the thrombotic fingerprint
parameter space will be executed in an analogous manner. The 384 run conditions
will be tailored in a manner such that the outputted thrombotic fingerprint will
cover the desired parametric space, while skewing run condition density to regions
of high parameter dependence and interaction.
6.2.1 OPTIMIZING WALL CONDITION
The process of selecting the optimal wall conditions and flow rate will be
accomplished by first testing a broad range of both conditions. The test tube walls
will be coated with specified compositions of fibrinogen, collagen, cryoprecipitate,
and thromboplastin. Fibrinogen and collagen will generate a baseline level of shear
dependent wall reactivity, as fibrinogen supports low shear rate platelet/wall
interactions, while collagen supports high shear binding in the presence of vWF.
Specifically, tests featuring collagen, fibrinogen, and a 1:1 collagen: fibrinogen
surface composition will be tested in conjunction with varying surface
concentrations of cryoprecipitate and thromboplastin. To establish a wide range of
wall reactivity, cryoprecipitate and thromboplastin will be considered in a variety of
concentrations both individually and in combination.
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6.2.2 OPTIMIZING FLOW RATE
Each of these surfaces will be considered at a low, low/moderate, moderate,
and high shear rate (50 s-1, 200 s- 1, 1000 s-1, 4000 s-1, respectively) to create
dynamic flow interactions yielding a total of 192 wall/flow conditions, which
comprises N=4 on two full 384-channel test runs. The data from this testing will be
analyzed in a three-dimensional plot of surface thrombus formation as a function of
wall surface composition and flow rate. Focus will be placed on regions of high
parametric dependence, which are defined by local peaks and troughs in signal
intensity. A priori determination of the location of these regions of interest is very
difficult, therefore once initial fingerprints are obtained, smaller, more-focused
studies will be performed to better characterize these regions using a higher density
of local parameter variation, for example, an increased number of flow rates under a
certain wall condition. Channel test conditions will then be skewed to better
represent these areas of change, while making an effort to minimize the number of
run conditions to adequately capture the parametric space.
6.2.3 OPTIMIZING BLOOD STATE
Once the thrombotic fingerprint has been optimized with respect to the wall
and flow conditions, the blood state will be modified to further expand the
thrombotic parameter space, and encompass the final axis of Virchow's Triad. In
addition, the blood state testing will serve to validate the thrombotic fingerprint as a
means of detecting thrombotic differences between blood samples. These
experiments will initially consider the optimized set of wall and flow conditions that
used whole blood samples, against low concentrations of known modifiers of
platelet function (ADP, epinephrine) and coagulation (cephalexin, PPACK). To limit
the amount of blood pre-activation, these samples will be drawn from healthy
volunteers according to approved protocols. These blood conditions that either
exhibit new peaks or troughs in surface thrombus formation, or augment the
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parameter dependence, will be incorporated into the final fingerprint data set as
enriched parameters. Finally, an iterative process will be utilized to determine the
optimal use of the 384 conditions of the high-throughput flow model.
6.3 ESTABLISHING A LIBRARY OF THROMBOTIC
FINGERPRINTS
Once the thrombotic fingerprint has been properly defined and optimized,
the focus of the project will shift towards establishing a limited library of thrombotic
fingerprints which can then be compared against standard clinical measures of
thrombosis. This period of time will be spent accumulating data, searching for
patterns, and generating hypotheses which can later be tested in a prospective
manner and correlated with clinical outcomes. Animal subjects will be exposed to
environmental stressors such as antithrombotic drugs commonly used in the clinical
setting. In particular, a variety of concentrations of aspirin (a ubiquitous platelet
inhibitor that decreases thromboxane production and platelet activation), plavix (a
platelet inhibitor that inhibits ADP dependent platelet activation and which is
commonly used in conjunction with aspirin to manage cardiac disease), and
Coumadin (a widely used inhibitor of the coagulation cascade, more specifically, of
the extrinsic pathway limb) alone, and in combination.
The thrombotic fingerprints of the animal models will then be collected and
compared. The resulting data will serve to compare the effects of these well
established medications on the thrombotic activity of the subject's blood. Although
these medications have found widespread use in the clinical environment, it
remains unclear what the optimal doses and durations of use should be, or if they
should be used in conjunction with one another. This is especially relevant in the
case of a given individual who, for example, may display drug resistance or be at a
particular risk for major bleed. The process of animal model validation of the flow
system may prove long and complicated, therefore a tentative animal testing plan
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has been developed early and may be modified as the animal model validation stage
approaches.
6.3.1 ANIMAL MODEL TESTING PLAN
Animal model testing will serve as the second to last major step in validation
of this model, while the last step involves validation of the flow system with the help
of healthy and diseased human subjects. During the animal testing phase, we will
consider farm swine exposed to a variety of anti-thrombotic agents. Four swine will
be maintained and exposed to aspirin, plavix, or coumadin alone or in combination.
The fingerprints derived from the animals will be assessed using a 50mL blood
sample under each "environmental state," in addition to the baseline control
fingerprint which will be obtained from each pig prior to drug administration, as
well as one week after completion of the experiment following cessation of all
medication. An additional blood sample of 10mL will be drawn for each control and
drug state to concurrently assess PT, aPTT, and platelet aggregation to ADP,
thrombin, epinephrine, and collagen as standard clinical measures of thrombosis.
6.3.2 EXPOSURE TO A SINGLE ANTI-PLATELET AGENT: ASPIRIN
A single pig will be administered aspirin in a dose escalating, step-wise
manner using doses that have previously tested in clinical trials, or are
approximately that in widespread clinical use for anti-platelet or anti-inflammatory
effect. Each dose will be given daily for one week to allow for the steady state
inhibition to be achieved. Immediately prior to initiating the administration of the
new dose, 60 mL of blood will be withdrawn, 50 mL of which will be run through
the high-throughput flow model, while the remaining 10 mL of blood will be used
for standardized thrombotic assessment.
6.3.3 EXPOSURE TO A SINGLE ANTI-COAGULANT AGENT: COUMADIN
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A second porcine model will be exposed to coumadin titrated to a goal INR
(International Normalized Ratio) of 1 to 4, ranging from a subtherapeutic to a
supratherapeutic level for most current clinical applications. Daily INR levels will be
monitored to ensure that the coumadin dose helps reach the required INR goal
level; the thrombotic fingerprint will then be obtained in parallel to the
standardized thrombotic assessment test results.
6.3.4 EXPOSURE TO COMBINED ANTI-COAGULANT AND ANTI-PLATELET
AGENTS: ASPIRIN AND COUMADIN
A third pig will be used to probe the interaction between anti-platelet and
anti-coagulant conditions, as a means of assessing how inhibition of each limb
interacts to alter the thrombotic fingerprint. Four conditions will be considered:
each a combination of high a low dose aspirin and coumadin (aspirin 25mg + INR 2
/ aspirin 25mg + INR 4 / aspirin 300mg + INR 4 / aspirin 300mg + INR 2). During
this process the aspirin will be administered daily for a week, at 25mg doses, along
with coumadin, which will be titrated to an INR 2. Once this level is achieved, the
thrombotic fingerprint data will be collected. Next, the INR will be titrated up to 4 by
increasing the coumadin dose, and fingerprint data will once again be collected.
Aspirin will then be increased to 300mg daily while the INR is maintained at 4, after
waiting a week, a blood sample will be collected and analyzed. Finally, the coumadin
dose will be reduced to allow the INR to fall back to 2, while a daily 300mg aspirin
dose is maintained. At this point, the last thrombotic data set may be collected. This
chronological organization of the procedure's environmental states will help to
minimize the total experiment time.
6.3.5 EXPOSURE TO DUAL ANTI-PLATELET AGENTS: ASPIRIN AND PLAVIX
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A fourth and final pig will be exposed to the condition of dual anti-platelet
agents and the drugs' interactions will be monitored. The specimen will be given
75mg of aspirin daily for a single week followed by collection of the thrombotic
fingerprint. The following week, no medication will be administered, and then once
again placed on a daily 75mg dose of plavix for a single week and data will then be
collected. The final environmental state will involve administration of a combination
of 75mg of aspirin and 75mg of plavix. After a week of exposure to the drug
combination, the final thrombotic results will be collected.
6.3.6 COMPILING THE THROMBOTIC FINGERPRINTS
The test plan provided above will allow for each swine to be maintained for
no longer than 5-6 weeks. Once the data for each environmental state in each
porcine model has been collected, inter-individual similarities and differences in the
four study pigs will be determined by comparing against the pre-exposure control
fingerprints. Next, the focus will be shifted to characterizing the effect of the altered
blood state by delineating similarities in fingerprints obtained from a pig exposed to
a given agent (aspirin or coumadin) from a drug concentration independent and
dependent point of view. The similarities and differences between the fingerprint
patterns of the two anti-platelet agents (aspirin and plavix), as well as the
differences between anti-platelet and anti-coagulant exposure (aspirin and
coumadin) will be examined.
The thrombosis model will be validated during this phase by verifying that
the data output contains information that can be correlated with the output of any
single traditional assay, for example, an elevated PT may correlate to characteristic,
graded changes in the fingerprint. The test data will be analyzed to show the unique
information provided by the model by characterizing the effects of multiple anti-
thrombotic agents on the fingerprint, such as in the dual anti-platelet or combined
anti-platelet/anti-coagulant therapy cases. Additional degrees of freedom will be
investigated, such as additional independent outputs, beyond those offered by the
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set of standardized clinical tests. This biologically relevant additional information
will provide proof of the enhanced correlative power of our novel assay. Special
attention will be paid to unexpected events, such as regions of the thrombotic
fingerprint that experience rapid topological change, which may be representative
of synergistic effects. An important secondary goal will involve gaining insight on
how the fingerprints may be represented in the best and most constructive manner
to allow for proper statistical comparison, which will be crucial to the system's
projected application in a clinical setting.
6.4 THE PATH TO CLINICAL APPLICATION
Once the thrombotic fingerprint system has been optimized, tested, and
correlative methods have been established, the system will be shifted towards
clinical applicability as soon as possible. The fingerprint library derived from animal
sources will continue to grow, incorporating environmentally and genetically
variant fingerprints as part of the scientific foundation. The main goal, though, will
be to apply the device to clinically relevant human test populations, such as in
studies to characterize the effect of fingerprint distribution in normal and diseased
populations. These studies will document the effects of drugs as well as known
procoagulant determinants (e.g. factor V Leiden, prothrombin gene mutation,
smoking, etc.) in these individuals. The effect of these environmental variations on
the thrombotic fingerprint will be explored as well as the interactions between the
variations.
The flow model will then have to be validated in a clinical setting, for
example, by characterizing levels of aspirin dosage based on achieving a desired
fingerprint pattern and following clinical outcomes. Another set of tests may
examine select populations at increased risk of thrombosis (e.g. pancreatic cancer)
and correlate the resulting fingerprint patterns with clinical outcomes. This
information could then be used to carry out prospective clinical trials involving
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prophylactic use of antithrombotic agents. One crucial aspect of the concept is that
for any given scenario, we hypothesize that there will be a reduced number of run
conditions which retain sufficient predictive power. The reduced set of run
conditions, once determined for a given scenario, will greatly reduce the assay
complexity and sample volumes, thereby greatly facilitating the transfer of the
thrombosis model technology to the clinical environment.
6.5 POTENTIAL IMPACT
The availability of this thrombosis model will enable basic science research
to more fully understand the complex thrombotic phenomena through investigation
of different blood, vessel wall, and flow condition interactions, as well as the
interactions of specific thrombotic activators and inhibitors. New patterns of
phenotypic expression, such as that induced by subtle polymorphisms (e.g. platelet
receptors), will be appreciated, allowing identification of new molecular pathways,
as well recognizing the importance of established pathways. Through correlation
with the clinical environment, the results will help to guide and focus research
directives by delineating bench-top phenomena with high clinical impact from those
without. Such a system could be used to drive the process of drug development,
functioning as a screen for novel thrombotic modifiers. Therapeutic ratios and
document toxicity may be determined prior to extensive clinical testing.
The clinical setting could greatly benefit from this technology: by grading a
particular individual's risk, counseling and preventative measures can be focused.
When needed, appropriate antithrombotic regimens can be selected and tailored to
the individual by determining proper drug titrations and durations of exposure. Safe
utilization of devices and implants which often require concurrent use of
antithrombotic agents (for example drug eluting coronary stents and plavix, or valve
replacement and coumadin), can be promoted. On a more fundamental level, the
general strategy forms a paradigm for translating in vitro test results to in vivo
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predictions. At the core of this new paradigm is the ability to blur the demarcation
between the areas of research, clinic, and industry, greatly fostering "bench-to-
bedside" translational efforts.
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APPENDIX A: MATLAB CODE TO CALCULATE INNER
DIAMETERS OF RESISTANCE TUBING
%This section finds the required pressure head
%to get a shear rate of 4000 in the largest tube
%diameter (300 microns)
%Length of test section
L_testcm= 10;
L test = L test cm/100;
%Length of resistance section
L_resistancecm = 15;
L_resistance = L_resistancecm/100;
%Diameter of test section
D_testmicrons = 300;
D_test = 300/10A6;
%Diameter of highest shear tube in microns
D_largest microns = 300;
D_largest = Dlargest-microns/1 0A6;
%Desired shear rate in largest tube (1/seconds)
shear = 4000;
%Viscosity at specified shear rate (kg/m*s)
viscosity = .004;
%Necessary pressure head (in Pa = N/mA2);
deltaP = (4*L test*viscosity*shear)/Dlargest +
(4*Lresistance*viscosity*shear)/Dlargest;
delta_P_kpa = deltaP/ 10^3;
%Now the pressure drop has been set, so the
%diameter of the other tubes can be determined.
%Desired shear rates
shear = [50 100 200 500 750 1000 2000 4000];
%Diameter of resistance sections
Appendix A 115
D_res = ((4*viscosity*L resistance.*D_test.^3.*shear)./(deltaP -
(4*viscosity.*Ltest. *shear)./D test)).A(1/4);
D_res = D_res';
D res microns = D res*10A6;
%Plots of the flow profiles, first finding the effective pressure
%drop in each test tube
delta_P_test = deltaP - (2*viscosity*L resistance*shear(:, 1)*(D-test/2).^3)/(D-res
(1,:)/2).^4;
r = [-Dtest microns/2:.O1:Dtestmicrons/2];
vz = (1/(2*viscosity))*delta_P_test*(((D testmicrons/I OA6)/2)A2-(r./1 0A6).A2);
plot(r,v z);
hold
xlabel('Radius [microns]')
ylabel('V z [m/s]')
for i = 2:length(D-res);
delta_P_test = deltaP - (2*viscosity*L resistance*shear(:,i)*(D test/2).^3)/(Dres
(i,:)/2).^4;
r = [-Dtestmicrons/2:.Ol:Dtestmicrons/2];
vz = (1/(2 *viscosity))*deltaP-test*(((D test-microns/ 1 OA6)/2)A2-(r./l 0A6).A2);
plot(r,vz);
end
%Shear rate plots
for i = 1:length(Dres);
r2 = [0:.O:Dtestmicrons/2];
y = -shear(:,i). *((r2.-(D test microns/2))/1 0A6);
plot(r2,y,'r');
end
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%Reynold's Number Calculation (density in kg/m^3)
density = 1060;
Re = (density*shear*(D-test/2)A2)/(8*viscosity);
figure(2)
plot(shear, Re);
xlabel('Shear Rate');
ylabel('Re');
%This code finds out the resistance diameters necessary
%while factoring in the Fahraeus Effect
%This section finds the required pressure head
%to get a shear rate of 4000 in the largest tube
%diameter (300 microns)
%Length of test section
L_testcm = 10;
L_test = L_testcm/100;
%Length of resistance section
L_resistancecm = 15;
L_resistance = L_resistancecm/100;
%Diameter of test section
D_testmicrons = 300;
D_test = 300/10A6;
%Diameter of highest shear tube in microns
Dlargest microns = 300;
Diargest = Dlargestmicrons/10A6;
%Desired shear rate in largest tube (1/seconds)
sheartest = 4000;
%Viscosity at specified shear rate (kg/m*s)
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viscositytest = .0007*log(Dlargest)+.0104;
%Necessary pressure head (in Pa = N/mA2);
delta P = (4*(Ltest+L_resistance)*viscositytest*shear-test)/D_argest;
delta_P_kpa = deltaP/10A3;
%Now the pressure drop has been set, so the
%diameter of the other tubes can be determined.
D_resvector = [50*10A-6:1*10^-7:300*l0A-6];
%Desired shear rates
shear test = [4000];
shear res (D-test./D-res).^3.*sheartest;
%In order to find the necessary resistance tube diameter
%you must find an equal resistance tube viscosity from the Fahraeus correlation
%and from the pressure drop equation
%In order to find the required tube diameters, you must change the sheartest
%value and plot the viscosityresi and 2 functions and find their point of
intersection
%viscosityresl = .0007*log(D resvector)+.0104;
%viscosityres2 = (D-resvector./(4*L resistance.*shear res)).*(deltaP -
(4*Ltest.*viscositytest.*shear test)./D test);
%figure(3)
%plot(D res,viscosity_resl);
%hold
%plot(D-res,viscosity_res2);
%xlabel('D_ res [meters]');
%ylabel('Viscosity [kg/m*s]');
%The final results from analyzing the graphs:
sheartestfinal = [50,100,200,500,750,1000,2000,4000];
D_resfinal = [8.3887*0^- 5,1.0071*10^-4,1.2103 * ^-4,1.5498* 0^-4,1.7345*10^-
4,1.8828*10-A
4,2.3251 *10^ -4,3 * 1 0A-4]';
figure(4)
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plot(shear testfinalD_resfinal);
xlabel('shear rate [I/s]')
ylabel('D res [m] (blue = Fahraeus compensation, red = no compensation)')
hold
plot(shear,D-res,'r')
Results before Fahraeus compensation:
Shear rate Resistance Diameter (microns)
50 88.4
100 105.3
200 125.5
500 159.0
750 177.2
1000 191.7
2000 234.8
4000 300.0
Results after
Shear Rate
50
100
200
500
750
1000
2000
4000
Fahraeus compensation:
Resistance Diameter (microns)
83.9
100.7
121.0
155.0
173.5
188.3
232.5
300.0
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